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CHAPTER I 
INTRODUCTION 
1.  LEGISLATIVE DEVELOPMENTS 
1.1  On  17  December '92, the Council  unanimously  reached a  decision of principle on 
the Proposal for a  Council Regulation laying down Community procedl;Jres  for the 
authorization of medicinal products for human and veterinary use and establishing a 
European  Agency  for  the  Evaluation  of Medicinal  Productsl,  consisting  of the 
Committee  for  Proprietary  Medicinal  Products  (human  medicines)  and  the 
Committee for Veterinary Medicinal Products (veterinary medicines).  Council also 
decided to consult the European Parliament on the change of the legal basis for this 
proposal  which  will  establish  a  new  'centralized'  Community  authorization 
procedure for  innovatory  medicinal  products,  from  Article  100A  of the Treaty to 
Article 235. 
In  addition,  the  Council  adopted  common  positions on  three  proposals  to  amend 
existing  Community  pharmaceutical  legislation  to  create  a  new  'decentralized' 
procedure  for  the  authorization  of  other  categories  of  human  and  veterinary 
medicinal  products  based  upon  the  principle  of  mutual  recognition  of national 
authorizations, but with binding Community arbitration in the event of disagreement 
between Member States. These new procedures, decentralized and centralized, have 
been  elaborated  from  the  experience  gained  with  the  current  Community 
procedures,  namely  the  'multi-state'  and  'concertation'  procedures.  This  report 
provides an  opportunity to  review the operation and  outcome of these procedures, 
especially as  this experience will  contribute substantially to  the preparation of the 
procedures for the future system. 
1.2 The analytical, pharmacotoxicological and clinical standards and protocols in  respect 
of the  testing  of medicinal  products  were  first  set  out  in  the  annex  to  Directive 
COM(90)283 of 14.11.1990 4 
75/318/EEC2•  Adaptation  to  technical progress is achieved  through  the Committee 
on the Adaptation to Technical Progress. 
Given  the  scientific developments  since  1975,  it  was  appropriate to  up  date  these 
requirements.  Further,  arising  from  the  adoption  of  Directives  89/341/EEC, 
89/342/EEC,  89/343/EEC,. 89/381/EEC,  the  so-called  "extension  directives",  it 
was  also  necessary  to  establish  the  requirements  for  the  testing  of immunological 
medicinal  products  consisting  of  vaccines,  toxins  or  serums  and  allergens; 
radiopharmaceuticals;  medicinal  products  derived  from  human  blood  or  human 
plasma. 
Following  a  complete  review  of  the  different  tests  and  trials  necessary  to 
demonstrate  the  quality,  safety  and  efficacy  of medicinal  products  by  the  CPMP 
and  its  working  parties,  and  a  favourable  opinion  of  the  Commitee  on  the 
Adaptation  to  Technical  Progress,  the  Commission  adopted  new  testing 
requirements.  These  requirements  are  set  out  in  Directive  91/507/EEC  which 
. entered  into  force  on  the  1.1.92,  to  coincide  with  the  entry  into  force  of the 
"extension directives". 
2.  CONTENT OF THE REPORT 
2.1  This report covers,  in  accordance with  the first paragraph of Article  15  of Council 
Directive 75/319/EEC,  the  operation  of the  procedure Jaid  down  in  chapter III  of 
that  Directive (i.e.  the  multi-state procedure) and  its effects on  the development of 
intra-Community trade, thus updating earlier reports3. 
2 
3 
In  performing  its  role  as  set  out  in  Directive  75/319/EEC,  the  Committee  for 
Proprietary Medicinal  Products (CPMP) gives an opinion as  to whether a ·particular 
medicinalproduct complies with  the  requirements set out in  Directive 65/65/EEC. 
In order to  facilitllte reading this report, references to Community pharmaceutical legislation cited arc 
summarized in chronological order in Annex  I. 
Reports from the Commission to the Council on the operation of the Committee for Proprietary Medicinal 
Products:COM(79)59 of22.2.1979;  COM(80)149 of31.3.1980; 
COM(81)363 of 13.7.1981;  COM(82)787 of3.12.1982; 
COM(84)437 of 3.12.1984, (explanatory memorandum); 
COM(88)143 of22.3.1988;  COM(91)39 of 15.2.91 5. 
Its  activities  are  therefore  not  restricted  to  applications  for  new  marketing 
authorizations,  but  also  include  consideration  of  the  appropriate  scientific  and 
administrative  requirements  for  the  submission  of  applications  for  marketing 
authorizations. The work of the CPMP does not end with  the decision  to grant or 
refuse a  marketing authorization.  The Committee maintains a  watchful eye on  all 
medicinal products on the market and is constantly active in  monitoring the safety 
and efficacy of these. 
2.2  On  the  basis  of its  expertise,  the  CPMP  has  also  supported  the  Commission  in 
international  discussions  on  technical  requirements  for  the  authorization  of 
medicinal  products,  the  exchange  of  scientific  knowledge  and  efforts  towards 
international  harmonisation  of  testing  requirement  for  pharmaceutical  products 
(International  Conference  on  Harmonisation  (ICH)).  Much  of  this  work  is 
accomplished by  the CPMP through  its  working parties and  expert groups,  which 
provide an invaluable support to the Committee and to the Commission. 
.  ' 
2.3 The present working document from  the services of the Commission  relates to  the 
period  between  1.1.1991  and  31.12.1992.  It  covers  the  global  activities  of the 
Committee for Proprietary Medicinal Products and its worlcing parties, and includes 
a brief statistical analysis of the operation of the two Community procedures (multi-
state  and  concertation)  for  the  co-ordination  of national  authorizations  to  place 
medicines  for  human  use on  the  market,  as  well  as  developments  in  the  area of 
pharmacovigilance and international harmonization/activities. 
In  order to  reflect the wide scope of activity of the Committee, all of these aspects 
are considered. 7 
CHAPTER IT 
STRUCTURE AND COMPOSITION 
1.  COMMI1TEE FOR PROPRIETARY MEDICINAL PRODUCTS 
1.1  The  Committee  for  Proprietary  Medicinal  Products  (CPMP)  was  established  by 
Directive  75/319/EEC  on  the  approximation  of provisions  laid  down  by  law, 
regulation or administrative action  relating to  proprietary medicinal products,  and 
is  charged  with  the  responsibility of giving an  opinion  as  to  whether a  particular 
medicinal product complies with the requirements set out in Directive 65/65/EEC. 
Furt~er, Directive 87/22/EEC requires that applications for marketing authorization 
relating  to  medicinal  products  for  human  use  referred  to  in  the  annex  of that 
directive i.e. biotechnology/high technology medicinal products, be brought before 
the CPMP for opinion. 
2.  MEMBERSHIP OF THE COMM11TEE 
2.1  The Committee for Proprietary Mediciml.l· Products,  in  accordance with  its Rules of 
Procedure (Ill/492177),  consists of one representative for each  Member State and 
one representative of the  Commission.  One alternate is  appointed  for  each of the 
representatives.  Each  member of the CPMP may  be accompanied  by up  to  three 
experts.  The  secretariat  of the  Committee  is  provided  by  the  services  of  the 
Commission. 
2.2 The Committee elects its chairman from amongst its members by absolute majority 
and secret ballot. The term of office of the chairman is three years,  renewable once 
only.  In  September  '88,  Professor D.  POGGIOLINI  was  elected  for a  first  term 
and in September '91  was re-elected for a further term. 8 
Professor POGGIOLINI had  been  preceded  as  chairman by Dr.  C.  TEUGELER 
(1983- 1988) and Dr. L. ROBERT (1977- 1983). 
2.3 The rules of procedure provide for two deputy chairmen; 
- one deputy  chairman  is  elected  by the  Committee in  accordance  with  the  same 
procedure as  the  chairman,  and  replaces  the  chairman  in  case of absence.  In 
September '91, Professor J.M. ALEXANDRE was re-elected deputy chairman. 
- the second deputy chairman is appointed by the Commission in order to conduct 
routine business on behalf of the Committee between meetings.  Mr.  F. SAUER 
continued to serve as deputy chairman during the period under review. 
2.4  A list of the membership of the CPMP (as of 31.12.  92) is given in annex 2. 
2.5 During the period under review, the Committee met on  17 occasions, which was the 
equivalent of 36 full  days of meetings. The working parties and expert groups met 
65  times  which  was  the equivalent of 101  full  days of meetings.  Between  CPMP 
and working party meetings,  137 days of meetings were organised (including travel, 
interpretation and documentation).  It is  clear that the resource requirement for the 
activities of the CPMP, both by the competent authorities of the Member States and 
by  the  Commission,  is  substantial.  With  the  work load  of the  CPMP  and  its 
working  parties  increasing  (see  chapters  III  and  IV),  the  urgent  need  for  the 
European Agency can be readily appreciated. 
3.  COMMUNICATION AND INFORMATION 
3.1  Given the wide range of activities of the CPMP, it is  important that the opinions of 
the Committee on pharmacovigilance, guidelines on the testing and development of 
medicinal products and positions on a number of issues of public health interest are 
available to the pharmaceutical industry, health care professionals and patients, and 
other interested parties.  A series of measures have been introduced to  publicise the 
existence of documents and to ensure their availability. 9 
3.2 The CPMP issues  a  Press  Release after each  of its  meetings.  In  the  release,  the 
numbers of opinions given for multi-state and concertation procedures are indicated, 
along with the  full  text of any pharmacovigilance opinion which has been adopted. 
All guidelines which are finalized are listed, as well as any draft guideline which is 
released  for  consultation.  International  liaisons  and  meetings  are  reported.  As 
relevant, items of special interest are included and in  some cases a  clarification of 
requirements may be indicated, such as: 
GCP:  In  March  '92,  the  CPMP  issued  a  clarification  regarding  the 
applicability  of  Good  Clinical  Practice  (GCP)  to  clinical  trials. 
"Commission  Directive 911507/EEC  requiring  all  phases  of clinical 
investigation to be designed, implemented and reported in  accordance 
with  good  clinical  practice came  into  force  on  1.1.92.  The  CPMP 
guideline  on  Good  Clinical  Practice  recommended  that  all  studies 
commencing after the  1.7.91 should be undertaken in accordance with 
GCP. The clinical expert as defined in  the Notice to Applicants (Jan. 
'89) is therefore asked to ensure that all studies commencing after this 
date  have  been  undertaken  in  accordance  with  GCP  and  to  clearly 
state this in  the introduction the Clinical Expert report in  an additional 
section  headed  'COI_npliance  with  GCP'. The expert should comment 
on any studies not complying with GCP and give a clear statement as 
to why the guidelines have not been applied.  In  this section the expert 
should  also  comment  on  studies  commencing  before  the  1. 7.  91, 
noting whether these were undertaken according to GCP. The expert 
should comment on any deficiencies in these studies." 
Hepatitis C:  In  December '92, "the Committee reaffirmed its position of 
17.3.92  regarding  the  need  to  screen,  for  hepatitis  C  (HepCV), 
plasma used in  the manufacture of medicinal products.  Only products 
which  have been  screened  for  the  absence  of antibodies  to  HepCV 
should be used  in  the production of medicinal products derived  from 10 
plasma,  as  of 1.1. 93.  For the  purpose  of clarification,  the  CPMP 
confirmed that the date of 1.1.  93 applies to the release of the finished 
product  by  the  manufacturer;  in  the  case of human  blood  derived 
products  used  as  an  excipient  the  date  of 1.1.93  applies  for  their 
incorporation  into  a  medicinal  product.  Companies  were  further 
reminded that the  screening  test  used  must be validated and  state of 
the art to avoid false negatives." 
3.3 The series 'The Rules governing Medicinal Products in the European Community in 
which there are 7 volumes, is prepared by the Commission and brings together the 
legislative  texts  relating  to  pharmaceuticals  as  well  as  the  publications  of  the 
CPMP, particularly in regard to guidelines for the testing of medicinal products and 
the submission of applications for marketing authorizations. 
These volumes are regularly updated, as follows: 
Volume I 
Volume II 
Volume III 
THE RULES GOVERNING MEDICINAL PRODUCTS 
IN THE EUROPEAN COMMUNITY 
The rules governing medicinal products for human use in  the 
European Commur)ity; Catalogue no.C0-71-91 631-EN-C. 
Notice to applicants for marketing authorizations for medicinal 
products for human use in  the Member States of the European 
Community (Second edition); Catalogue no.CB-55-89-293-EN-C 
Guidelines on the quality, safety and efficacy of medicinal 
products for human use; Catalogue number CB-55-89-843-EN-C: 
Addendum (July 1990) CB-59-90-936-EN-C 
Addendum no.  2 (May 1992) ISBN 92-826-4550-9 11 
Volume IV  Good Manufacturing Practice for medicinal products 
Catalogue number  C0-71-91-760-EN-C 
These texts, as  well  as  Volumes  V,  VI and  VII on  Veterinary Medicinal  Products, 
are on sale at the:-
Office for Official Publications of the European Communities 
2 rue Mercier 
L-2985 LUXEMBOURG 
tel.  (352) 49 92  81  I fax  (352) 49 00 03 
3.4  In  operating  the  . Community  procedures  for  multi-state  and  concertation 
applications,  the  CPMP  has  developed  a number of Operating  Procedures.  Whilst 
these texts have always been generally available,  it was considered that reference to 
the texts would be simplified by preparing a compilation into a Procedures Manual. 
The first edition will be finalized in May  '93. 
3.5  In  a further  effort to  increase  transparency,  the  Committee  has  agreed,  in  March 
'91,  that  the  assessment  report  prepared  in  the  concertation  procedure  would  be 
made available to  the applicant.  For other issues of general interest,  such  as  in  the 
case of the  report on  Hypnotics,  the  Committee has  agreed  to  prepare a summary 
document which would be made available. 
4.  WORKING PARTIES AND AD HOC GROUPS 
4.1  The  CPMP  supports  its  scientific  activities  with  expertise  from  the  competent 
authorities of the  Member  States.  Given  this  large  pool  of resource,  a number  of 
structures have been set up. 
- Working  parties:  a working  party  gathers  experts  from  all  12  Member  States, 
and  generally  treats questions relating  to  the  manufacture,  demonstration  of safety 
and  efficacy  of medicinal  products  and/or  administrative  procedures.  Although 12 
there is a tendency  for  the same expert to  follow  developments within  the working 
party, the attendance 'at any given  meeting  will be determined by the content of the 
agenda.  Working parties generally  meet  twice a year,  although  additional  drafting 
group meetings, for specific topics,  may also be called. 
- Ad hoc groups: Experience has shown  that flexible structures which can respond 
to  specific needs and  which  can  regroup expertise either of differing disciplines or 
specialist interests,  are  required.  Thus  ad  hoc  groups  are formed  in  order. to  deal  · 
with clearly identified  tasks/questions.  The number of meetings of an  ad  hoc group 
~ill depend  on  the  time  scale  given  for  the  resolution  of the  problem  and  the 
complexity of the issue. 
4.2  The supporting structures of the CPMP are illustrated in Figure 1.  Connecting lines 
have not been drawn,  so as  to emphasize the fluidity between the  main  Committee, 
the working parties and expert groups. 
Erficacy 
Pharmaco 
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4.3  The  chairman  of the  CPMP  nominates  an  expert  as  chairperson  of a  working 
party/ad hoc  group,  which  is  endorsed  by  the  CPMP.  In  December  '91,  the 
following were appointed as chairpersons, for a term of three years: 13 
+  Biotechnology/Pharmacy working party:  Professor G. Vicari 
+  Efficacy working party: Professor Dr. U. Gundert-Remy 
+  Operations working party: Dr. D. Jefferys 
+  Pharmacovigilance working party: Professor J. Schou 
+  Quality working party: Dr. A.  Artiges 
+  Safety working party: Dr. M .. Burns 
The following accepted to act as chairperson/co-ordinator for the specific topic: 
+  Ad hoc Blood Products: Dr. D. Sandoval 
+  Ad  hoc Radiopharmaceuticals: Dr. K.  Kristensen 
+  Ad  hoc Hypnotics: Professor J.M. Alexandre 
+  Ad hoc Herbal Remedies: Professor A. Hildebrandt 
+  Ad  hoc Over The Counter (OTC's): Dr. S. Mela 
4.4. The activities undertaken in  the working parties/ad how groups during the last two 
years,  the  numbers  of meetings  held  and  guidelir"  41  developed  are  summarised 
hereunder: 
4.4.1.  Biotechnology/Pharmacy:  The  biotechnology/pharmacy  working  party  assists 
the CPMP in  reviewing the biotechnology quality aspects of applications received in 
accordance with List A of the concertation procedure (see chapter IV).  In  addition, 
the  working  party  developed  guidelines  on  'Validation  of  virus  removal  and 
inactivation  procedures';  'Harmonization of requirements  for  influenza vaccines'; 
'Medicinal  products  derived  from  human  blood  and  plasma';  'Guidelines  for 
minimizing the risk of transmission of agents causing spongiform encephalopathies 
via medicinal products';  'Allergen products'; and  'Biotech headings for the Notice 
to  Applicants'.  With  the inclusion of quality aspects of biotechnology products on 
the programme for ICH 2 (see page 51), the  workir.~ party is also collaborating in 
this  international  activity.  The  working  party  met  11  times,  which  was  the 
equivalent of 22 meeting days. 14 
4.4.2.  Efficacy:  This  working  party  considers  the  scientific  requirements  for  the 
demonstration of efficacy of medicinal products. The working party has prepared a 
number  of general  clinical  guidelines  as  well  as  clinical  guidelines  on  specific 
therapeutic classes of medicines.  During  1991-1992,  a  number of' guidelines were 
finalized,  including  'Clinical·  investigation  of  hypnotic  medicinal  products'; 
'Investigation  of  bioavailability  and  bioequivalence';  'Summary  of  Product 
Characteristics (SPC) of Benzodiazepines used as hypnotics';  'SPC of B-adrenergic 
blocking  agents'.  The  working  party also participated,  along  with  other  working 
parties,  in  the  preparation  of  the  topics  for  the  International  Conference  on 
Harmonization (ICH). The working party met on 5 occasions,  for the equivalent of 
9 days. 
4.4.3.  Operations:  This· working  party  elaborates  administrative  requirements  and 
procedures for submisSions through  the multi-state and  concertation procedures. It 
. met  on  12  occasions,· equivalent  to  18  days,  and  developed  a  large  volume  of 
documents  both  for internal  use  by  the  CPMP and  for  use  by  the  pharmaceutical 
industry.  Guidelines  include  'Summary  of  Product  Characteristics  (SPC)'; 
'Abridged applications'; 'EC application format';  'CPMP list of allowed terms'; as 
well  as  internal  operating  procedures  for  the  multi-state  and  concertation 
procedures,  a  'check-in'  procedure  for  dossiers  and  a  guideline  on  'Assessment 
reports'. The working party  is  currently preparing a  revision  to  the administrative 
part of the Notice to  Applicants (to be known as Notice to Applicants '93, Volume 
IIA), a draft of which was released for consultation in  December '92. The revisions 
of Volume liB will commence in  1993, for finalization during 1994. 
4.4.4.  Phannacovieilance: This working party continued its work on the harmonisation 
of approaches towards the monitoring and collection of information on adverse drug 
reactions  (ADR's).  A  number  of  guidelines  were  prepared  and  adopted: 
'Pharmacovigilance exchange of information within the working party';  'Procedure 
for  causality classification  in  pharmacovigilance  in  the  EC';  updating  the  'Rapid 
alert system. The working party met on  11  occasions, for a total of 12 days. 15 
4.4.5. Quality:  This  working  party  reviews  analytical  testing  and  development 
requirements for demonstration of the quality of medicinal_ products.  A number of 
new guidelines were prepared, 'Ionizing irradiation in the manufacture of medicinal 
products';  'Specifications  and  control  tests  on  the  finished  product';  'Quality  of 
prolonged  release oral  solid  dosage  forms'.  The working  party  Iiaises  with  other 
bodies  including  the  European  Pharmacopoeia.  It  collaborated  actively  in  the 
preparations  for  the  ICH  conference  in  November  '91  and  subsequent  ICH 
meetings. The working party met on 8 occasions, which equated to  14 days. 
4.4.6. Safety:  This  working  party  considers  preclinical  toxicological  and 
pharmacological issues, both in  regard to specific substances and generiu principles. 
The possible association of Noscapine,  an  alkaloid of opium,  with  polyploidy was 
reviewed by the group and  subsequently led  to  the CPMP opinion of 4.12.92 (see 
annex  3).  The application  of Good  Laboratory  Practice  to  safety  tests  was  also 
examined by the group and  the CPMP issued  a statement on  this  in  February  '93. 
In  addition  to  the  preparation  of the  guideline  on  'Non-clinical  local  tolerance 
testing of medicinal  products';  the working party participated actively· in  the  ICH 
discussions. The working party met on 4 occasions, equivalent to 7 meeting days. 
4.4.7.  Ad  hoc  groups:  the  ad  hoc  groups of the  CPMP,  particularly  those  concerned 
with  the co-ordination  o( the  review  of the  'extension'  products  met  during  this 
period also: 
Radiophannaceuticals:  this  ad  hoc  group  met  7  times  (10  meeting  days)  and 
agreed a programme for  the review of radiopharmaceuticals,  as well  as preparing 
summaries of product characteristics for  many  of these  products.  Two guidelines 
were  prepared,  on  Radiopharmaceuticals  and  on  radiopharmaceuticals  based  on 
monoclonal antibodies, and also specific elements for the Notice to  Applicants and 
for the Pharmaceutical Expert Report 16 
Blood products: the ad  hoc group co-ordinating the review of medicinal products. 
derived  from  human  blood  or human. plasma met on two occasions,  and  with  the 
co-operation  of experts  working  in  the  Member States,  twenty  core SPC's have 
been finalized. 
Herbal Remedies:  In  response  to  submissions  from  the  European  Scientific  Co-
operative for  Phytopharmaceuticals (ESCOP)  , an  ad hoc group met for two days 
and prepared assessment reports on  six  monographs. This was transmitted from  the 
CPMP to ESCOP in  October '92. 
Hypnotics:  Following  the  referral  in  accordance  with  Article  11  of  Directive 
75/319/EEC (see page 45) the CPMP established an ad  hoc group of rapporteurs to 
assess the relative benefit/risk of all  short acting hypnotics.  The ad  hoc group met 
on 4 occasions,  for the equivalent of 6  meeting days,  and presented a preliminary 
report to the CPMP in December '92. This report will be finalised during the early 
part of 1993. 
OTC's: In  response to  submissions  from  AESGP,  and  arising  from  the  combined 
. efforts  of the  experts  in  the  Member States,  a  number of draft  SPC's  for  OTC 
products (i.e. medicinal products available without a prescription: over-the-counter) 
have been released for consultation. 
.  . 
4.5 An  important ingredient in  the success of the supporting  structures of the CPMP is 
the flexibility, co-operation and hard work shown by the experts who participate in 
discussions.  Thus  working  parties  have  worked jointly with  other working parties 
and/or with ad  hoc groups, collaborating as full  groups or smaller drafting groups; 
rapporteurs  have  worked  together  on  applications,  assessment  reports  and 
guidelines;  experts  and  co-ordinators  have  liaised  with  international  partners 
involved in  the ICH process. 17 
With  the heavy  work  load  of the  Committee,  the working  parti~s and  the ad  hoc 
groups, the need to ensure excellent communication between experts, constant flow 
of documents and  sufficient resources  to  allow  experts  to  meet,  has  been  clearly 
identified  as  a  priority.  Thus  the  favourable  position  of Council  regarding  the 
establishment of the  European  Agency  for  the  evaluation  of Medicinal  Products 
points  the  direction  for  the  future  and  serves  to  encourage  those  involved  to 
continue their excellent efforts. 19 
CHAPTER III 
MULTI-STATE PROCEDURE 
1.  PRINCIPLES OF THE MULTI-STATE PROCEDURE 
1.1  The legal  rules governing the  "multi-state"  procedure are set out in  Chapter Ill of 
Directive  75/319/EEC,  as  amended  by  Directive  83/570/EEC.  A  'Notice  to 
Applicants'  explaining  the  multi-state  procedure  was  published  in  1989  (Rules 
governing  medicinal  products  in  the  European  Community,  Volume  II)  and  is 
currently being revised. The revised document which will be referred to as Volume 
IIA is expected to be available in September '93. 
1.2 The objective of this Community procedure is to make it easier for a person who has 
already  obtained  a  marketing  authorization  in  one  Member State  (the  rapporteur 
country) to get further marketing authorizations for the product concerned in  other 
Member States.  On the basis of the same  documentation, and taking the marketing 
authorization  granted  by  the  first  Member  State  into  due  consideration,  the 
authorities of the  Member States  to  which  the application  is  addressed  have  120 
days to grant authorization to market the product in  their country or in  exceptional 
circumstances to formulate reasoned objections. 
2.  SCOPE OF THE PROCEDURE 
2.1 The multi-state procedure may be used  for full  or abridged applications and certain 
limited amendments (variations).  A  full  application is one for which  the results of 
physico-chemical,  biological,  microbiological  tests;  pharmacological  and 
toxicological  tests;  and  clinical  trials  are  presented  (an  innovative  product).  An 
abridged  application  is  one  for  which  the  results  of  pharmacological  and 
toxicological tests or the results of clinical  trials are not required provided that the 
conditions of Article 4. 8. (a) of Directive 65/65/EEC have been met. 20 
2.2 For amendments (variations),  the multi-state procedure may be used  for medicinal 
products  which  have  already  used  the  procedure  in  cases  where  the  amendment 
(variation)  would  change  the  summary of product characteristics  (SPC),  and  for 
which  the  same  composition,  specification,  method  of manufacture  etc.  for  the 
finished  product  is  agreed  in  all  Member  States,  and  for  which  a  unanimously 
favourable  opinion  was  given  with  an  agreed  harmonised  summary  of product 
characteristics (known as  'the' SPC),  . The continued  harmonization of 'the' SPC 
can thus be maintained using the multi-state procedure. 
2.3 Directives  89/342/EEC,  89/343/EEC and  89/381/EEC came into  effect  from  the 
1.1.  92,  and  extended  the  scope  of Directives  65/65/EEC  and  75/319/EEC  to 
immunological  medicinal  products  consisting  of vaccines,  toxins  or  serums  and 
allergens;  radiopharmaceuticals;  medicinal  products derived  from  human  blood or 
human  plasma  ..  Therefore,  from  the  1.1.92,  medicinal  products  of ·these  classes 
which  have  been  approved  in  accordance  with  the  criteria· laid  down  by  the 
Community directives may also use the "multi-state" procedure. 
3.  USAGE OF TilE PROCEDURE 
3.1  A  multi-state  procedure  is  started  by  the  submission  of  an  application  for  a 
marketing  authorization  in  two  or  more  Member· States.  The  application  is 
submitted by the applicant in  each of the concerned Member States referring  to  the 
procedure  laid  down  in  Chapter  III  of Directive  75/319/EEC,  as  amended  by 
Directive  83/570/EEC.  The  secretariat of the  CPMP  is  notified  by  letter  of the 
intention to start a multi-state procedure. 
The  application  is  'checked  in'  i.e.  validated  as  containing  all  the  necessary 
documents,  by  the  concerned  Member  States  within  10  working  days  of receipt 
using  a  commonly  agreed  procedure.  After  all  concerned  Member  States  have 
confirmed receipt of the application,  the CPMP secretariat notifies all  the  Member 
States and the applicant of the start of the 120 day period referred to in Article 9 (3) 
of Directive 75/319/EEC. 21 
3.2 During the period under review,  126 new procedures were notified to the prodedure. 
By  31.12.92,  119  of these had  been  'checked in' and  the period of 120 days  had 
commenced. 
Thus the rate of increase of usage of the multi-state procedure, already signalled in 
the report of 1991, has been maintained and even increased. 
Figure 2: Usage of  the multi-state procedure 
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3.3  As  a  multi-state  procedure  co-ordinates  a  number  of  simultaneous  national 
applications in the Member States, it is interesting to note that these 119 procedures 
correspond  to  the equivalent of 752  national  applications  i.e.  an  average of 6.32 
national applications per procedure. This average figure  illustrates a  movement by 
companies towards the involvement of a greater number of Member States in multi-
state procedures. By contrast, during the period, 1988-1990 the average coverage of 
a  multi-state  procedure  was  5.20.  Indeed  the  average  coverage  of a  multi-state 
procedure  has  consistently  exceeded  5  countries,  despite  the  reduction  of  the 
required  number of concerned countries from  five  to  two  as  a  result of Directive 
83/570/EEC. 22 
3.4  The  role  of  rapporteur  in  the  multi-state  procedure  continues  to  be  unevenly 
distributed amongst the Member States,  in  that applicant companies appear to  have 
marked preferences for some Member States to act as rapporteur. 
Figure 3: rapponeurs in the multi-state procedure 
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Conversely, the concerned Member States receiving applications through the multi-
state procedure continues to reflect the same relative pattern as in previous years. 
Figure 4: Recipient Member States in the multi-state procedure 
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* In  accordance  with  the  terms  of the  Act  of Accession,  Portugal  implemented 
Directives 65/65/EEC, 75/318/EEC, 75/319/EEC, 78/25/EEC, 83/570/EEC on the 
1 January 1991  and accepted multi-state applications only from that date. 
4.  OtrrCOME OF TilE PROCEDURE 
4.1  As  in  previous  reports  it  must  be reported  that  the  multi-state procedure has  not 
lived up to the spirit of the directive which introduced it, since the safeguard clause 
has been used on every occasion i.e. objections had been raised in every procedure, 
and every single multi-state application has been referred for a CPMP opinion, with 
the exception of a new effervescent presentation of an already authorized medicinal 
product for which no objections were raised within the 120 day period .. 
Despite the fact that the safeguard clause is used so frequently,  it is evident that the 
procedure  is  attractive  to  some  of industry,  in  that  the  level  of  usage  is  still 
increasing.  From companies which  have used  the procedure,  it would  appear that 
the multi-state procedure (in its current form) offers advantages and disadvantages: 
Advantages: 
a)  for selected Member States, faster approval times, especially for 
innovative or semi-innovative medicinal products; 
b)  for small companies, which do not have subsidiaries in all Member States, 
the procedure offers simultaneous handling and co-ordination of 
applications in concerned countries, allowing for efficient and intensive 
utilization of limited resources; 
c)  a single dossier, for which Member State flexibility regarding language 
requirements is perceived as positive; 
d)  the strict adherence to the limit of 120 days for receipt of objections 
serves  to save time. 24 
Disadvantages: 
a)  the lack of acceptance of the first authorization, typified by the systematic 
referral to the CPMP 
b)  varying interpretation amongst the Member States of identical data; 
c)  the delay in issuing the marketing authorization document by  the Member 
State following the CPMP opinion; 
d)  the difficulty of achieving a harmonized SPC due to  'precedent' in 
concerned Member States. 
4.2  The  extent  to  which  the  safeguard  clause  is  used  would  seem  to  indicate  that 
concerned Member ,States completely  re~assess a multi-state application, looking for 
issues  to  raise.  With  the  notable exception  of Luxembourg,  which  recognises  the 
authorizations of other Member States,  the frequency  of systematic objections has 
even increased for some Member States and only slightly declined for others. 
Figure 5: Frequency of  objections in the multi-state procedure 
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4.3 The CPMP has  given  184  opinions for multi-state procedures up  to and including 
December '92. Of these,  171  have been favourable and 13 unfavourable. 
Figure 6: Outcome of  multi-state opinions 
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4.4 However, as the opinion of the CPMP is  not legally binding,  the opinion does not 
always  express  a  unanimous  view.  Therefore,  the  practice  is  to  identify  any 
Member State which diverges from  the Committee opinion, giving reasons for such 
divergence. 
Of the 171  positive opinions,  124 have been unanimous. 
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4.5  As  already  mentioned,  a  disadvantage of the current  multi-state  procedure  is  the 
delay in the issuing of the marketing authorization documents by the Member States 
following the CPMP opinion.  Article 14.3 of Directive 75/319/EEC, as amended, 
requires notification by the Member states to the Committee of decisions on  action 
arising from opinions of the CPMP. Unfortunately, delays considerably longer than 
the  prescribed  60  days  have  been  seen  although  some  Member  States  have 
introduced administrative procedures to ensure a  rapid  and  efficient processing of 
the opinion. 
The multi-state procedure does not provide for an  appeal  mechanism,  so that once 
an  opinion  is  given,  the  national  appeal  procedures  are  used.  Nonetheless  the 
CPMP closely  follows  the outcome of final  decisions  of the concerned  Member 
States  until  all  concerned  Member States  have  notified  their  final  decision  (see 
annex 4 for completed procedures). 
Of  those  multi-state procedures which  are now  complete,  i.e.  those  for  which  all 
concerned Member States have notified their decision with  regard to the application 
as presented during the multi-state procedure, the delay following the opinion (from 
the date of the CPMP opinion  to  the  date of the  last  notification  by  a  concerned 
Member State) has exceeded the allowed 60 days of the Directive (Article 14.3 of 
Directive 75/319/EEC) as the following chart shows: 
Figure 8: Dday of  national notifications following multi-state opinions 
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Whilst the trend in  the notification of decisions following  CPMP opinion is in  the 
right  direction,  clearly  it  is  a  matter  which  needs  to  be improved.  In  addition, 
figure 8 refers only to those procedures which are completed.  Of the  184 opinions 
given by the CPMP in the multi-state procedure, 86 remain to be completed by the 
Member States, some for as long as 18 months. 
In  order to  reduce this delay,  the CPMP has  taken the initiative of including with 
every opinion, a summary of product characteristics. Whilst every effort is made to 
achieve 'the' SPC, there are many instances where it is  not possible to arrive at an 
agreement on the precise wording of the SPC. 
5.  EVALUATION OF THE MULTI-STATE PROCEDURE 
On  the  basis  of the  experience  outlined  above,  it  is  possible  to  identify  some 
_  emerging trends and features of the multi-state procedure: 
a)  The Multi-state procedure remains  attractive  to  industry,  as  confirmed  by  the 
continued increase in  the humbers of applications. 
b) The vast majority of opinions are positive, consistent with the philosophy of the 
Directive  which  provides  for  Member  States  to  take  into  due  consideration  the 
marketing authorization of another Member State. 
c)  However,  there  are  dissenting  views  in  approximately  30%  of cases.  which 
means that the objective of the single market with free movement of products is not 
being achieved. 
d)  As  the  opinion  is  not  legally  binding,  it  is  not  always  possible  to  resolve 
dissentions in an opinion. 28 
e)  The delays  in  notification  of national  action  following  the  CPMP  opinion,  and 
the  consequential  delay  in  market  access  is  a  cost  of  'non-Europe'  for  the 
pharmaceutical industry. 
f)  The  experience  gained  in  the  multi-state  procedure  can  provide  invaluable 
pointers  regarding  the  operation  of the  decentralized  procedure  in  the  future. 
Therefore  the  CPMP  will  draw  on  this  experience  in  putting  into  practice  the 
legally supported basis of mutual recognition in the decentralized procedure. 29 
CHAPTER IV 
CONCERT  A  TION PROCEDURE 
1.  PRINCIPLES OF TilE CONCERTATJON PROCEDURE 
1.1 The legal rules governing the concertation procedure are set out in  Council Directive 
87/22/EEC  of  22  December  1986.  A  'Notice  to  Applicants'  explaining  the 
concertation procedure was published in  1989 (Rules governing medicinal products 
in  the  European  Community,  Volume  II)  and  is  currently  being  revised.  The 
revised  document  which  will  be  referred  to  as  Volume  IIA  is  expected  to  be 
available in September '93. 
1.2 The objective of the concertation procedure is to provide a mechanism of arriving at 
uniform  decisions  throughout  the  Community  on  applications  for  marketing 
authorizations  for  medicinal  products  developed  by  means  of new  biotechnology 
processes  and  other  high  technology  medicinal  products.  This  means  that  any 
questions relating to  such products must be resolved at Community  lev~l within the · 
CPMP before  any  national  decision  is  reached  concerning  the  marketing  of the 
product concerned. 
Moreover the Commission publishes a list of the products in  respect of which  the 
procedure  has  been  used.  Such  products  benefit  from  the  ten  year  period  of 
protection  of innovation  afforded  by  Article 4.  8  (a)  of Directive  65/65/EEC  as 
amended  by  Council  Directive 87/21/EEC of 22 December  1986,  from  their first 
date of authorization  in  the  Community.  In  the  case  of Zidoduvide  which  had 
already  been  authorized  prior to  the  introduction  of the  procedure,  the  10  years 
which  starts  from  20.6.90  only  applies  to  the  List  B  indication  (asymptomatic 
patients).  The first  list was published  in  COM(39)91  of 15  February  1991  and  is 
updated hereunder: 30 
- Fi~ure 9: Products which have benejiJed f,-_om  the concertation JJ!Ocedure 
INN name  Brand name  Authorizntion  First  Member 
holder  authorization  State 
OUJ  0RTHOCLONE  Cila~  3.6.86  Fr 
rONA Human Growth Hormone  NORDITROPIN  Nordisk Gentofte  28.4.88  Dk 
rONA Insulin  INSULIN  Novo lndustri  8.7.88  Dk  . 
AIS 
Erythropoetin  EPREX  Cila~  4.8.88  Fr 
Mab purified Factor VIII  MoNOCLATEP  Armour  3.10.89  It 
Pharmaceutical 
rDNA Interleukin  PROLEUKIN  Eurocetus  23.6.89  Sp 
Antimyosin Fah-DTPA  MYOSCINT  Centocor Europe  13.6.89  It 
rONA Hepatitis B vaccine  ENGERIX- B  Smith Kline  10.12.86  Be 
French Labo 
Erythropoeitin  RECORMON  Boehringer  1.3.90  Dk 
Mannheim 
rONA Human Growth Hormone  GENOTROPIN  Kahi Biopharma  5.5.88  Be 
Zidoduvine (asymptomatic  RETROVIR*  Well come  20.6.90  Dk 
_patients)  Foundation 
Glucagon  HYPOGON*  Novo Nordisk  29.7.91  Dk 
rONA Human Growth Hormone  HUM A  TROPE  Lilly Industries  12.10.87  Dk 
Alteplase,  1  Omg  ACTILYSE  Boehringer  10.6.87  Fr 
lngelheim 
rONA Human Growth Hormone  ESKATROPE  SmithKiine  28.8.91  Dk 
Beecham 
Interferon alpha-2h (Hepatitis)  INTRON A  Schering Plough  24.1.85  lrl 
r-metHug-CSF  NEUPOGEN  Hoffmann La  15.3.91  UK 
Roche 
HAll A monoclonal antibody  CENTOXIN  Centocor  2.4.91  Nl 
Dental Tetrac2'Ciine fibre  ACTISITE*  Alza  30.7.91  It 
lmmunoconjugate CYT-103  ONCOSCINT  Eurocetus  1.7.91  Be 
rONA Human Growth Hormone  SAIZEN  Ares Serono  21.5.91  It 
Eflomithine  ORNIDYL*  Merrell Dow  29;3.91  Be 31 
INN name  Brand name  Authorization  First  'Member 
holder  authorization  State 
Interferon 2 alpha (Hepatitis)  ROFERON A  Hoffmann La  2.7.86 
Roche 
I  nlt!rferon alpha  WELLFERON  Well come  3.3.86 
nl(ins)(Hepatitis)  Foundation 
rDNA Human Insulin  HUMULIN  Lilly_ Industries  1.9.82 
GM-CSF Molgramostim  LEU COM AX  Schering  23.10.92 
Plough/Sandoz 
Mab purified Factor IX  MONONINE  Armour  5.10.92 
gamma Interferon  IMUKIN  Boehringer  20.7.92 
lngelheim 
Didanosine  VIDEX*  Bristol Myers  12.5.92 
Squibb 
Pentostatin  NIPENT*  Parke Davis  5.1.93 
* Products accepted by the CPMP as being within List B of the annex to Directive 87/22/EEC. 
2.  SCOPE 
2.1  Medicinal products from  new biotechnology processes as  defined  in  the  Annex  to 
Directive 87/22/EEC are included as "List A products". The concertation procedure 
is  obligatory  for  all  medicinal  products  developed  by  means  of the  following 
biotechnological processes: 
+ recombinant DNA technology; 
+ controlled  expression  of genes  coding  for  biologically  active 
proteins  in  prokaryotes  and  eukaryots,  including  transformed 
mammalian cells; 
+  hybridoma and monoclonal antibody methods 
UK 
UK 
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2.2  Medicinal  products  of high  technology  as  defined  in  the  Annex  to  Directive 
87/22/EEC  are  eligible  to  be  "List  B products".  High-technology  products  with 
novel  characteristics  as  defined  in  List  B of the  Annex  to  Directive  87/22/EEC 
may,  at  the  request  of the  applicant,  be  accepted  for  consideration  under  the 
concertation procedure. 
~he following categories are eligible for List B status:-
+ medicinal products developed by other biotechnological prOcesses 
which,  in  the  opinion  of  the  competent  authority  concerned 
constitute a significant innovation; 
+ medicinal  products  administered  by  means  of  new  delivery 
systems  which,  in  the  opinion  of  the  competent  authority 
concerned constitute a significant innovation; 
+ medicinal produ'tts containing a new substance or an entirely new 
indication  which,  in  the  opinion  of the  competent  authority 
concerned are of significant therapeutic interest; 
+ new  medicinal  products  based  on  radio-isotopes  which,  in  the 
opinion  of  the  competent  authority  concerned  constitute  a 
significant innovation; 
+ medicinal  products the  manufacture of which  employs rrocesses 
which,  in  the  opinion  of  the  competent  authority  concerned 
constitute a significant  technical  advance  such  as  2-dimensional 
electrophoresis under micro-gravity. 
2.3 In order to maintain the same conditions of marketing  for products which have been 
the subject of an  opinion of the  CPMP under the concertation procedure,  the same 
application  for  amendment  should  be  submitted  to  all  Member  States  which  have 
authorized the product.  Normally,  the Member State which  acted  as  rapporteur for 
the  original  application  would  act  as  rapporteur  for  the  variation,  although  this  is 
not a requirement. 33 
The procedure for the examination of a variation is identical whether the product is 
List  A  or  B,  and  may  include  an  accelerated  procedure  or  a  full  procedure, 
depending  on  the  nature of the variation.  Very  minor changes  requiring  only  an 
assessment  report  from  the  rapporteur will  usually  follow  a  written  procedure 
(within  30 calendar days).  More major changes  (such  as  a  major  new  indication 
with considerable clinical data)  may need a procedure almost as complex as a  full 
application. 
3.  USAGE 
3.1  Between  1.1.91  and  31.12.92,  19  new  concertation  procedures  were started.  This 
marked a significant increase in the usage of the procedure. 
Figure 10:  Usage of  the concertation procedure 
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3.2  The  concertation  procedure  may  be  used  for  medicinal  products  derived  from 
biotechnology (obligatory),  or at the choice of the applicant,  for  high  technology 
products. In  1990 there was a surge of biotechnology applications, as most of those 
medicinal  products  derived  from  biotechnology  w!"'ich  had  been  authorized  by 
national procedure before the entry into force of Directive 87/22/EEC came within 34 
the scope of the concertation procedure. This was due to the clarification issued  by 
the CPMP in July '89 regarding amendments to any medicinal product derived from 
biotechnology.  1992 has seen a substantial growth in the number of high technology 
applications.  Many of these  would  fall  into the general  meaning of 'orphan drugs' 
and it is an important signal that a centrally co-ordinated procedure for access to the 
single  market  favours  even  medicinal  products  for  rare  diseases  which  would  not 
necessarily have a large market. 
3.3 The CPMP  has given  30 opinions  in  the concertation  procedure.  All  of these  have 
been  positive.  However,  3 applications  were  withdrawn  by  the  applicant  prior  to 
opinion. Of these 30 opinions, 26 were unanimous.  Of the 4 which were dissenting, 
two  opinions  had  I  Member  State  dissenting,  one  opinion  had  2  Member  States 
dissenting and  in the case of one opinion, five Member States dissented. 
A major success of the concertation procedure is the extent to which  'the' summary 
of product characteristics (SPC)  is  achieved  - in  21  of the 30 procedures.  In  these 
cases,  the Member States agree a harmonized  single SPC.  Thus  not only does  the 
same  physical  product  move  throughout  the  market,  but  the  same  product 
information for health care professionals applies in all Member States . 
. 3.4 Any amendment of the particulars and  documents of the  marketing authori1.ation,  or 
amendment  to  the approved  summary of product characteristics,  must  be submitted 
to  the  competent  authorities.  In  the  case  of medicinal  products  which  have  been 
considered through the concertation procedure,  such amendments (often referred to 
as  variations) avail. of a co-ordinated  procedure thrcmgh  the  CPMP,  thus  ensuring 
the continued harmonization of the product and its particulars. 
The  innovative  nature  of medicinal  products  using  the  concertation  procedure  is 
such  that  improvements  to  the  quality  of the  product  are  a  frequent  source  of 
variations.  So  too  is  the  extension  of  the  clinical  usage  of  the  product. 
Pharmacovigilance data may,  on occasions,  lead  to an  amendment of the summary 
of product characteristics. 35 
The many and  diverse nature of variations  in  the concertation  procedure has  very 
substantially increased the work load of the CPMP. 
Figure 11: Extent of  variations in the concertation procedure 
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3.5 Unlike the multi-state procedure, the concertation procedure does not set a minimum 
number of countries to which application must be made.  Instead, application can be 
made to as few as  1 (there is an  exemption from  the procedure for List A products 
which are to  be market~ during five years in  only one Member State).  However, 
all members of the CPMP must receive at least the summary of the dossier (Part 1). 
In practice, almost all concertation procedures apply to all  12  Member States. 
The concertation procedure also differs  from  the  mulit-state one by virtue of the 
number of Member States actually concerned with each procedure. Whereas for the 
multi-state procedure the mean coverage is 6.3 Member States per procedure, in the 
concertation  procedure  it  generally  all  12  Member  States,  except  in  exceptional 
cases. 36 
Figure  12: Coverage of  Member States by concertation procedures 
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3.6 Another difference with the multi-state procedure is the fact that no decision on the 
application  is  made by  any Member State prior to  a concertation procedure.  Thus 
the assessment of the application is done at the same time in all Member States and 
is  led  by  a  rapporteur.  The  applicant  may  choose  the  rapporteur  by  virtue  of 
submitting the application  in  that  Member State first.  It is  the  practice,  however, 
for  applicants  to  liaise  with  the  competent  authority  before  commencing  a 
concertation procedure and before making a submission. 
The  task  of rapporteur  is  more  evenly  distributed  between  the  Member  States. 
Additionally, the role of co-rapporteur allows for a second Member State to support 
the first in the assessment of the application. 
Figure  13: Rapportl'urs in thr conc:atation procc•dure 
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3.  7  The duration  of the  concertaton  procedure has  been  queried  on  many  occasions. 
Previously it  was  not possible to give any indication as the  number of procedures 
was too small to draw any reasonable conclusions. However, as 30 procedures have 
now reached an opinion, it is possible to provide an overview. 
The length of the assessment phase,  taking  the date of submission of the applicant 
as day 1,  up to the date of the opinion of the CPMP is summarized hereunder: 
Figure 14: Length of  concertarion procedures/months 
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3.8 However,  of concern  in  the  concertation  procedure just as  it is  in  the  multi-state 
procedure,  is  the delay  in  notification  of decisions  fo11owing  the  CPMP opinion. 
Further,  in  the  concertation  procedure,  a  period  of only  30 days  is  allowed  for 
notification of such decisions.  Given  that only 5 out of the possible 30 procedures 
have been completed,  it is possible to  indicate the length of time between the date 
of the CPMP opinion and the date of notification of a decision by the last Member 
State concerned for these 5 procedures: 38 
A  = 57 months;  B = 31  months;  C  = 29  months;  D  = 7  months;  E  = 29 
months, 
SIDe~  the  eoncertation  procedure  deals  with  medicinal  products  derived  from 
biotechnology  and  also  high  technology  products,  it  is  clearly  in  the  interest  of 
patients that this area is targeted as a priority aspect for improvement. 39 
CHAPTER V 
OTHER CPMP OPINIONS 
l,  REFERRALS TO THE CPMP 
1.1  The  CPMP  may  be called  upon  to  give  an  opinion  as  to  whether  a  particular 
medicinal product complies with  the requirements set out in  Directive 65/65/EEC. 
In  addition  to  the  multi-state  and  concertation  procedures  already  described  in 
Chapters III and IV,  the CPMP may  be requested  to  formulate an  opinion on  the 
basis of Articles 11  or 12 of Directive 75/319/EEC, as amended. It is the policy of 
the CPMP that opinions issued  in  accordance with  articles  11  and  12  of Directive 
75/319/EEC are made publicly available.  Therefore,  in  annex 3, all  such opinions 
-issued during 1991-1992 are reproduced. 
The  synthesis  of  the  different  aspects  (efficacy,  safety,  quality,  and 
pharmacovigilance)  involved  in  the  establishment  of  the  benefit/risk  ratio  of · 
medicinal products means that there is a continuous exchange of information within 
the CPMP and its specialised working parties. Thus matters may be considered by 
the pharmacovigilance working party,  one of the other specialised working parties 
(efficacy, safety, quality, biotechnology), or by an  ad  hoc group convened for that 
.  . 
express purpose. 
1.2  Article  11  of  Directive  75/319/EEC  allows  either  a  Member  State  or  the 
Commission  to  refer a  matter  to  the  CPMP for  opinion.  Such  cases  would  arise 
when applications· for a particular medicinal product have been submitted in  several 
Member States and one or more have granted a marketing  authorization while one 
or more have refused it. The  referral could also occur where one or more Member 
States  have  suspended  or revoked  a  marketing  authorization  while  one  or more 
Member States have not done so. 40 
The person responsible for placing the medicinal product on  the market is informed 
:o(.a.ny decision of tbe CPMP to issue a reasoned opinion, and  may generally avail 
Qfth,e opportunity for  written or oral explanation to the CPMP. 
1.3 Article  12  of Directive allows the competent authorities of the Member States,  in 
specific cases where the interests of the Community are involved, to refer a matter 
to the  CPMP before reaching a decision on a request for a marketing authorization 
or on the suspension or revocation of an authorization. 
The CPMP  has  identified  a  number  of areas  where,  given  the  current  state  of 
scientific knowledge, it is considered that Article 12 should be used: 
- in  the case of products for  the primary treatment of AIDS  (which  may,  at  the 
request of the applicant, use List B of the concertation procedure) 
- for applications following  the List B (concertation) procedure,  where the CPMP 
has  already  accepted  that  the  medicinal  product  is  of Community  interest,  the 
withdrawal by the applicant of the application from  the concertation procedure with 
reapplications on a national basis, 
- in  the case of information  from  pharmacovigilance,  where the benefit/risk ratio 
of a medicinal product must be reassessed. 
The CPMP may amend the above cases in  the light of scientific progress, and  this 
would be announced through the CPMP press release. 
The  CPMP  considers  that,  when  practical,  the  applicant  or  the  marketing 
authorization holder would be offered the opportunity to  make a submission, orally 
or in  writing, before the CPMP issues its opinion. 41 
2.  PHARMACOVIGILANCE IN THE FRAMEWORK OF TilE CPMP 
2.1 The CPMP has for many years been concerned with  issues of pharmacovigilance. 
The system of pharmacovigilance, which operates nationally, is concerned with the 
collection  of  information  useful  in  the  surveillance of medicinal  products,  with 
particular  reference  to .adverse  reactions  in  human  beings,  and  the evaluation  of 
such information scientifically. In addition to the consideration of matters referred 
to  it  under  Articles  11  or  12  of Directive  75/319/EEC,  the  CPMP  exchanges 
information on all  decisions taken  (Articles 30 and  33 of Directive 75/319/EEC). 
Further, in  Directive 89/341/EEC (Article 3) Member States must notify the World 
Health  Organisation  of measures  taken  by  them  or by  manufacturers  on  action 
which may affect public health in  third countries. 
The consideration of pharmacovigilance issues by the CPMP comprises a number of 
specific areas of activity. 
2.2 Pharmacovigilance Opinions 
During  the  period  under  review,  the  Committee  prepared  7  pharmacovigilance 
opinions, on the following substances, some of which were an updating of previous 
opinions e.g Glafenine,  Fl~narizine: 
Opinion no.  Active Substance  Trade Name  Date 
8 revision 1  Glafenine/floctafenine  Glifanan  13 2 1991 
6 revision 1  Flunarizine  Sibelium  12 3 1991 
6 revision 2  FJunarizine  Sibelium  11  9 1991 
10  Fenoterol  Berotec  1191991 
11  Triazolam  Hal cion  11  12 1991 
8 revision 2  Glafenine  Glifanan  14 1 1992 
12  Noscapine  Different in the  4  12  1992 
Member States 42 
2.  3 Rapid Alert 
:The procedure for rapid alerts which had  been in  operation since 1979 was updated 
io.:Julv '91  (III/3917/91). The rapid alert system has been used on 22 occasions. 
These  alerts  concerned,  for  the  most  part,  notifications  of decisions  taken  at 
.  national level.  As  such, the evaluation process, which necessarily takes some time, 
had already been completed.  Such evaluations however tended  to be based on the 
data available to the relevant authority from  its own market, without the benefit of 
input from  other authorities.  The CPMP  is  currently  working  on  improving  this 
system  of ·alert  so  as  to  avail  of data  coming  from  all  Member  States  in  the 
assessment of pharmacovigilance information, prior to  any decision being taken.  A 
num_ber of guidelines have been prepared to facilitate this. 
In  July  '91, the CPMP adopted a guideline on  the exchange of pharmacovigilance 
information  (III/3366/91).  The objective  of this  system  is  the  exchange  of any 
specific pharmacovigilance information that,  after a first evaluation in  the Member 
State,  does  not  require  urgent  action  but  could  facilitate  the  early  detection  of 
potentially  important  problems.  This  allows  all  Member  States  to  share  their 
information and to prepare a more informed position. 
2.3 Causality Classification 
A  vaiiety  of different  systems  for  the  assessment of the  likelihood  of a  causal 
relationship in case reports of suspected ADR's have been developed. Three major 
causality classifications have been recognised for use at Community level: 
::.Category.  "A":  reports  including  good  reasons  and  sufficient  documentation  to 
.  assume a causal  relationship, in  the sense of plausible, conceivable, likely, but not 
necessarily highly probable. 
Cdtegory  "B ": reports containing sufficient information to accept the possibility of a 
causal  relationship,  in  the  sense of not  impossible and  not  unlikely,  although  the 
connection  is  uncertain  or  doubtful,  for  example  because  of  missing  data  or 
insufficient evidence. 43 
Category  "C": reports where causality is, for one or another reason, nor assessable, 
e.g. because of insufficient evidence, conflicting data or poor documentation. 
A fuller explanation of this system is given in 'Procedure for causality classification 
in  Pharmacovigilance  in  the  European  Community  (III/3445/91),  which  is 
reproduced in  Chapter VI. 
2.4 Pharmacovigilance Hearings 
When  considering  pharmacovigilance  information,  the  CPMP  draws  on  the 
information  available  within  the  Member  States,  from  international  sources  and 
generally invites the marketing authorization  holder (or holders)  to  submit written 
explanations.  In  addition,  before the finalization  of a  pharmacovigilance opinion, 
the  applicant/marketing  authorization  holder  may  present  orally  before  the 
Committee. 
During the period under review,  (1991-92) 2 pharmacovigilance hearings with  the 
CPMP were held. 
3.  PROHIBITED MEDICINAL PRODU(.'TS CDIRE(.'TIVE 75/319/EEC ARTICLE 33.4} 
3.1 Article 33.4 of Directive 75/319/EEC requires the Commission to publish annually a 
list of the medicinal products prohibited in the Community. 
Due  to  Directive 65/65/EEC,  which  provided  that  no  medicinal  product  may  be 
marketed  until  formal  approval in  the  form  of a marketing authorization  has been 
given,  all  medicinal  products must be deemed  to  be prohibited  unless  specifically 
authorized.  For  the  purposes  of compiling  a  useful  listing  therefore,  the  term 
'prohibited'  is  taken  as  meaning  those  medicinal  products  which  have  been 
authorized and for which the authorization is withdrawn/revoked. 44 
It  should  be  noted  that prohibitions are imposed  by  the Member States not  by  the 
Commission.  Prohibition can  take various  forms,  including outright revocation  of 
the  marketing  authorisation, . or  temporary  suspension  for  a  period  while 
precautionary measures/studies are carried out.  In the latter case,  the matter may be 
resOlved  quickly  and  the  product  either  reinstated  on  the  market  or definitively 
withdrawn. 
Until the Agency envisaged under the proposals for the future system for evaluation 
of  medicinal  products  is  in  place,  the  role  of  the  CPMP  is  limited  to  the 
consideration  of  reported  adverse  reactions  to  marketed  products,  which  are 
referred  to  it  in  accordance  with  Articles  11  and  12  of Directive  75/319/EEC. 
Article 14.3 of the same directive requires Member States to inform the Committee 
of actions taken  pursuant to  the publication of an  opinion.  Therefore the  following 
listing covers those products which have been  'prohibited'  in  one or more  Member 
States, following a CPMP pharmacovigilance opinion. 
3.2 Glafenine 
In  March  '89, the Belgian  authorities requested  the Committee,  in  accordance with 
Article  12  of  Directive  75/319/EEC,  to  give  an  opinion  on  Glafenine 
(GLIFENAN).  Glafenine  is  a  peripheral  analgesic  for  which  a  number  of side-
effects,  particularly  anaphylactic  reaction  and  intrarenal  crystallisation,  had  been 
reported. 
The  CPMP  considered  the  available  information  and  issued  a  first  opinion  in 
December  '89,  recommending a number of safeguard  measures  including  limiting 
the  supply  of Glafenine  to  non  renewable  prescription  and  amendments  to  the 
summary  of product  characteristics.  This  opinion  was  revised  in  February  '91, 
when  all  Member  States  were  invited  to  compile  and  report  on  the  up-to-date 
situation.  In  the light of further information, both  from  the marketing authorization 
holder  and  competent authorities of the  Member  States,  the  Committee issued  an 
opinion  in  January  '92,  concluding  that  the  signal  first  identified  in  spontaneous 
surveillance had been confirmed by a Dutch epidemiological study, and  that the risk 
of anaphylactic reaction  with  Glafenine was  higher than  for  other analgesics.  Thus 45 
the benefit/risk ratio was considered to be negative and the marketing authorization 
should be withdrawn. 
France and Portugal did not concur with the scientific assessment of the Committee. 
They did not share the conclusions of the Dutch epidemiological study and therefore 
considered that there was no new information available, and Glafenine, aside from 
anaphylactic  reaction,  had  less  of some  other side-effects  than  other  analgesics. 
Therefore the product was still considered by those 2 countries to have a favourable 
benefit/risk  ratio  when  used  as  a  second  line  treatment  in  patients  where  other 
analgesics were inappropriate. 
Following  the  CPMP opinion  of January  '92,  Italy,  the  Netherlands  and  Spain 
informed  the  Committee that  the  marketing  authorizations  for  medicinal  products 
containing  Glafenine  had  been  revoked.  France  suspended  the  marketing 
authorization for one year and Portugal notified a suspension of 90 days. 
Belgium and Luxembourg had withdrawn the marketing authorizations in December 
'91; the company had withdrawn the product from the German market in  1983; and 
no application for m·arketing authorization had been submitted in  Denmark, Ireland 
and the United Kingdom .. 
Therefore the substance is not presently marketed in the Member States. 
3.3 Triazolam 
On 2 October '92, Triazolam (HALCJON) was temporarily suspended in the United 
Kingdom.  The French and Dutch authorities immediately requested  the Committee 
to  give  an  opinion,  in  accordance  with  Article  11  of Directive  75/319/EEC. 
Triazolam is a short acting hypnotic for which a number of side-effects,  including 
memory  impairment and  neuro-psychiatric  effects,  had  been  reported.  Medicinal 
products  containing  0.25  mg  and  0.125  mg  Triazolam  were  authorized  in  all 46 
Member  States,  although  the  authorization  of  both  dosage  forms  had  been 
temporarily suspended in  the UK on 2.10.91. 
·1M CPMP, upon preliminary consideration, issued a Position Statement in October 
'91, recommending a  number of safeguard measures including limiting  t~e-supply 
of  Triazolam  to  small  packs  and  amendments  to  the  summary  of  product 
characteristics  emphasising  the  short-term  use  of  the  product.  The  Committee 
considered it necessary to review the large volume of information submitted by the 
company,  as  well  as  data  in  the  application  dossier  and  information  from 
pharmacovigilance.  Therefore  rapporteurs  were  appointed.  The  report  of  the 
rapporteurs was considered in December '91  when the Committee issued an opinion 
confirming the safeguard measures taken,  particularly with  regard to the maximum 
dosage  of 0.25mg,  the  narrow  and  very  precise  indications  as  well  as  contra-
indications for the product, the absolute importance of short term  usage (not more 
than  10 days) which  had been reinforced by the introduction of small pack sizes in 
all Member States. 
The Committee further decided  to  complete the work done by  the rapporteurs and 
invited  them  to  fully  assess  the  relative  benefit/risk  ratio  of  all  short  acting 
hypnotics. This review was undertaken by the ad  hoc group on  Hypnotics (see page 
11).  The  report  of the  ad  hoc  group  is  expected  to  be  finalized  in  1993  and 
thereafter the CPMP will  publish a scientific report. 
Since the opinion,  the  UK  has continued the suspension .of both  dosage forms  and 
the matter is currently suh judice. 
On  30.12.91, France suspended the 0.25 mg.  presentation for one year; on 9.1.92; 
Spain  suspended  the  0.25  mg.  presentation  for  six  months  and  renewed  this 
suspension  for  a  further  6  months  on  10. 7.92.  Both  Member  States  nonetheless 
adhered  to  the continued the authorization of 0.25mg dosage recommendation  (by 
virtue of the 0.125mg presentation, which is available on their markets). 47 
Thus  the  0.125  mg  presentation  is  authorized  in  11  Member  States,  while  the 
0.25mg  is  authorized  in  all  except  the UK,  France and  Spain.  Pack  sizes  were 
reduced in all  Member States and information on the product for both  health care 
professionals and patients was strengthened. 
3.4 Medicinal products of bovine origin 
Following the adoption by the CPMP of the guideline  'Guidelinesfor minimizing 
the  risk  of  transmission  of  agents  causing  spongiform  encephalopathies  via 
medicinal  products'  in  December  '91,  a  number  of  Member  States 
suspended/withdrew  medicinal  products  of bovine  origin.  In  many  cases  it  was · 
possible  to  reformulate the  product and  therefore  the  suspension  was  lifted.  The 
reformulation of a  number of products is  still  on-going  in  the  Member States.  A 
report on  the position  is  being prepared by  Portugal and  will  be available during 
1993. 
3.5 Mumps vaccine 
In September '92, the company SmithKline Beecham voluntarily withdrew all  their 
vaccines (Pariorix, Rimparix and Pluserix) which contained the Urabe Am 9 strain. 
Data  collected  in  active  surveillance  studies  in  the  United  Kingdom  suggested  a 
frequency  of meningitis  following  vaccination  that  was  higher  than  previously 
reported.  However,  the  company  liaised  with  the  competent  authorities  of the 
Member States and the CPMP to ensure that the discontinuation of the products was 
implemented  with  the  least  possible  disruption,  in  order  to  maintain  public 
confidence in the national vaccination programme. 
3.6 Herbal Remedies 
In  the course of its review of the proposals from  ESCOP (see page 11), the CPMP 
compiled  a  listing of herbs  and  herbal  derivatives  which  had  been  withdrawn  for 
safety reasons from one or more Member State markets. 48 
H~RBIJ/ERBAL  PART OF PLANT  Reason for withdraw  I 
DERIVATIVE 
AcJUJ,itum  (all species)  ALL PARTS  Contains aconitine and other 
toxic alkaloids 
Angeli~'  arch~ngeHca L.  FRUIT, HERB  Contains phototoxic 
furanocumarins 
Aristolochia (all species)  ALL PARTS  Contains aristolochin acids, 
strong carcinogen,  . 
genotoxicity 
Artemisia cina (BERG.)  FWWERBUD  Contains the toxic lactone 
WILLKOMM.  santonin 
Berberis vulgaris L.  BARK:, ROOT  Contains the alkaloid 
BARK, ROOT  berberine 
Borago officinalis  HERB, FLOWERS  Contains pyrrolizidine-
alkaloids with genotoxic, 
carcinogenic and hepatotoxic 
properties 
Byronia (all species)  ROOT  Cytotoxic cucurbitacines 
Chenopodium  ESSENTIAL OIL  Contains the toxic principle 
ambrosioides L. var.  ascaridole 
anthelminthicum (L.) A. 
GRAY 
Chrysanthemum vulgare  FLOWER, HERB  May contain essential oil with 
(L.) BERNH.  neurotoxic thuione  . 
Claviceps purpurea (FR.)  SEC  ALE  Contains toxic ergot-alkaloids 
TULASNE  CORNUTUM 
(SCLEROTIUM) 
Convolvulus scammonia  RESIN  Drastic laxative with irritant 
L.  properties 
Croton tiglium L.  SEED, FATTY OIL  Contains tumour promoting 
FROM SEED  phorbol diesters  ' 
Cynoglnssum offidnalc L.  IIERH  contains pyrrolizidinc-
alkaloids with genotoxic, 
carcinogenic and hepatotoxic 
pro_perties 
Dryopteris filix mas (L.)  RHIZOME  Constituents are highly toxic, 
SCHOTT  especially with increased 
absorption 
Exogonium purga  ROOT, RESIN  Drastic laxative action with 
(WEND) BENTH.  irritant action 49 
Juglans regia L. \  FRUIT-SHELL  May contain the 
naphtoquinone jug  lone which 
is mutagenic and possibly 
carcinogenic 
Juniperus sabina L.  HERB  Toxic herb 
Ledum palstre L.  HERB  Contains essential oil which 
is a potent irritant of GI tract, 
kidneys and urinary tract 
Mallotus phillipinensis  GLAND AND  Drastic laxative action which 
(LAM.) MULLER-ARG.  TRICHOMES  may cause severe 
(KAMALA)  gastroenteritis, diarrhoea and 
vomiting when taken in 
higher doses 
Ocimum basilicum L.  ESSENTIAL OIL  Contains high amounts of 
estragole which is genotoxic 
and a carcinog_en in  rodents 
Petasites hybrldus (L.)  LEAF  Contains pyrrolizidine 
GAERT. MEYER et  alkaloids with genotoxic, 
SCHREB.  carcinogenic and hetatotoxic 
properties 
Petroselinum crispum  FRUIT  Contains significant amounts 
(MILL.) Nym. ex  of essential oil with toxic 
A.W.HILL  apiole 
Pulsatilla vulgaris  HERB  Higher doses may irritate teh 
MILLER  kidneys and urinary tract; 
pregnancy is an absolute 
contra-indication 
Ruta graveolens L.  HERB, LEAVES.  Causes phototoxic reactions, 
genotoxic, can be fatal 
Rubia tinctorum L.  ROOT  Contains lucidin with 
genotoxic and probably 
carcino}:!;enic activity 
Sassafras albidum  WOOD, ROOT  Contains essential oil with 
(NUTT  .) NEES  carcinogenic and genotoxic 
safrole 
Senecio (all species)  HERB, ROOT  Contains pyrrolizidine 
alkaloids with genotoxic 
carcinogenic and hepatotoxic 
properties 
Strychnos nux-vomica L.  SEED  contains alkaloids, especially 
strychnine 50 
Symphytum (all species)  HERB, LEAF, ROOT  Contains pyrrolizidine 
internal use  alkaloids with genotoxic, 
carcinogenic and hepatotoxic 
properties 
Teucrium chauaedris L.  HERB  Hepatotoxicity 
Tussilago farfara L.  FLOWER, ROOT  Contains pyrrolizidine 
alkaloids with genotoxic, 
carcinogenic and hepatotoxic 
properties 
Vinca minor L.  HERB, LEAF  Haematological changes 
(leucocytopenia, 
lymphocytopenia, reduced  .  globulin levels) have been 
observed in rabbits 
A  number  of  other  herbs/herbal  derivatives  were  also  considered.  Further 
examination of the benefit/risk of some other herbs/herbal  derivatives,  and  under 
what conditions of use, ·will be undertaken during 1993. 51 
CHAPTER VI 
INTERNATIONAL ACTIVITIES AND TRADE 
1.  INTERNATIONAL EXCHANGE 
1.1  The CPMP d~s not limit its considerations to developments within  the European 
Community, but also monitors and reviews scientific innovations and developments 
internationally.  Many  countries  and  regions  have  expressed  interest  in  the 
mechanisms and results of the harmonization activity of the Community. 
Thus,  for example, the standard application format (Notice to Applicants) adopted 
by  the  12  Member States  is  now  acceptable  in  all  the  member  countries  of the 
Nordic  Council  and  the  European  Free  Trade  Association  (EFTA),  Australia, 
Canada, South Africa and most eastern European countries. 
1.2 Therefore,  the CPMP has  introduced a practice of international consultation on all 
draft guidelines and  technical  standards.  Thus  many  countries and  regions  in  the 
world have the opportunity to comment on the technical and scientific requirements 
for the development of medicinal products in the EEC. 
2.  INTERNATIONAL CONFERENCE ON HARMONIZATION 
2.1  The first  International  Conference on  Harmonization of technical  requirements for 
, registration  of pharmaceuticals  for  human  use  (ICH .1)  took  place  in  Brussels  in 
November  '91.  This  major  international  conference  was  jointly  supported  and 
organised  by  the  Commission  of the  European  Communities,  the  US  Food  and 
Drug Administration,  the Japanese Ministry of Health  and  Welfare,  together with 
the  pharmaceutical  industry  as  represented  by  the  International  Federation  of 
Pharmaceutical  Industry  Associations,  the European  Federation of Pharmaceutical 
Industry  Associations,  the  US  Pharmaceutical. Manufacturers  Association  and  the 
Japanese Pharmaceutical Manufacturers Association. 52 
The International Conference on Harmonization is distinctive in  that it is supported 
both  by  regulators and  the industry in  order to  facilitate greater harmonization of 
technical  requirements  in  the  three  regions.  ICH  1  in  Brussels  was  a  success  as 
progress was made in  all  three areas of safety, quality and  efficacy;  Following on 
from this success, ICH 2 is currently being planned for Orlando in October '93. 
To prepare for ICH 2,  the Steering Committee mets on  two occasions each  year, 
along  with  more  than  100  experts  from  the  three  regions.  In  March  '93,  the 
Steering Committee met in  Brussels with  the expert groups on  quality,  safety and 
efficacy to prepare positions before the conference in Orlando in October '93. 
2.2 Eleven topics were considered and developed during ICH 1 and a further  17  will be 
prepared for ICH 2: 
Quality  Safety  Efficacy 
ICH  I  Stability testing  Short and long term  Clinical safety 
toxicity 
Specifications  Reproductive toxicity  Special 
_populations: Geriatrics 
Pharmacopoeias  Biotechnology  Good Clinical Practices 
Timing of toxicity  Dose Response studies 
studies 
ICH 2  Stability ll  Carcinogenicity  Population exposure in 
clinical trials 
Analytical validation  Genotoxicity  Clinical safety reports 
Impurity testing  Toxicokinetics  Clinical study reports 
Pharmacopoeial issues  Dose response studies 
Biotechnology  Ethnic factors in the 
acceptability of foreign 
data 
With  so  many  topics  for  consideration,  the  CPMP and  its  working  parties  have 
structured  the discussions  on  ICH  such  that  it  now  takes  a  regular  place  in  the 
agendas of all meetings.  A co-ordinator for the CPMP has been nominated for each 
of the symposia: Quality: 
Safety: 
Efficacy: 
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Dr. A.C. Cartwright 
Professor R.  Bass 
Professor J.M. Alexandre 
The CPMP has further illustrated its commitment to international harmonization- by 
accepting  to  release  for  consultation  three  draft  tripartite  guidelines  developed 
through the ICH process: 
draft  Stability testing of new drug substances and products (May '92); 
draft  Reproduction toxicity (December '92); 
draft  Clinical studies in special populations: Geriatrics (December '92). 
3.  COUNCIL OF EUROPE 
3.1 The convention relating to the elaboration ofa European Pharmacopoeia was signed 
in  1964 within the framework of the Council of Europe. The European Community  . 
gave legislative force to the standards of the European Pharmacopoeia in  Directive 
75/318/EEC as amended by Directive 911507/EEC. 
In  November  '89,  a  pro~ocol  for  the  accession  of the  EEC  to  the  European 
Pharmacopoeia was  opened  for  signature.  The Protocol  was  ratified by all  states 
which  are parties  to  the  Convention.  Therefore,  the  Community  will  become  a 
direct member of the Convention during 1993. 
3.2  A  framework  agreement  was  set  up  in  1992,  between  the  Commission  and  the 
Council of Europe,  which provides for the development,  over the next four years, 
of standards for biological medicines described in the European Pharmacopoeia. 54 
4.  RELATIONS WITII EFfA/EEA 
4.1 During 1991-92, experts from EFf  A and the Nordic Council of Medicines attended 
all  meetings of the Quality, Safety and Efficacy working parties of the CPMP. All 
draft texts  for guidelines and  technical  requirements  were also circulated  to  both 
bodies  for  consultation.  This  close  co-operation  facilitated  the  acceptance  of the 
'acquis communitaire' in the pharmaceutical sector during negotiations for the EEA 
(European Economic Area) agreement. 
5.  TRADE IN PHARMACEUJ1CALS 
5.1 The total value of the world pharmaceutical market (excluding China and the former 
Soviet Union) in  1991  was estimated to  have been around ECU 140 billion. Taken 
as a whole, the European Community constitutes the largest pharmaceutical  market 
in  the world, accounting for a third of the tota1 4• 
4 
Latin America 
15.59Q 
EFPIA in Figures, 1991  - 1992 
Europe 132.79Q 
East Europe 
(3.99Q 
Asia, Africa, 
Australia 125.5%1 55 
5.2 From  the  previous  reports  (cited  above)  and  from  the  many  economic  analyses, 
approximately 67% of sales of medicinal products in the Community come from the 
Member States. This level has been relatively constant for the last decade. 
Figures  for  the  geographical  distribution  of  exports  (for  bulk  and  finished 
pharmaceuticals) are given in annex 5, as well as trade and other statistics. 
5.3  Article  15  of Directive  75/319/EEC  requests  that  this  report  should  cover  the 
operation of the multi-state procedure and  its effects on  the development of intra-
Community  trade.  Even  though  the  numbers  of  multi-state  and  concertation 
procedures have continued to grow, they would represent less than  10%  of the total 
number of applications made in  the Community each year. Therefore the impact on 
intra-Community trade has not been possible to quantify, but it may be assumed not 
to be substantial. 
However, what has been significant has been the progress in  harmonization which 
in  now  complete.  From  the  stand  point  of .  achieving  the  single  market,  there 
remains  the  finalization  of the  legislative  support  to  the  future  system  - which 
allows access  to  a  single market either through  the  'door' of a  Member State or 
through a Community  'door'. Thereafter it will  be up  the pharmaceutical  industry 
to  avail of the opportunity of the largest single market  for  pharmaceuticals in  the 
world. Annex 1 
Annex 2 
Annex 3 
Annex 4 
Annex 5 
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Chronological listing of pharmaceutical legislation 
relating to human medicinal products EEC  DIRECTIVES  RELATING  TO  THE  MARKETING  AUTHORIZATION  FOR 
MEDICINAL  PRODUCTS  FOR  HUMAN  USE 
COUNCIL  DIRECTIVE  65/65/EEC of  26  January  1965  on  the  approximat-
Ion  of  provisions  laid down  by  law,  regulation or  administrative 
action relating to proprietary medicinal  products  (O.J.  n·  22  of 
9.2.65) 
COUNCIL  DIRECTIVE  75/319/EEC  of  20  May  1975  on  the  approximation 
of  provisions  laid down  by  law,  regulation or  administrative 
action relating  to proprietary medicinal  products  (O.J.  n·  L 147 
of  9.6.75) 
COUNCIL  DIRECTIVE  75/318/EEC of  20  May  1975  o~ the  approximation 
of  the  laws  of  Member  States relating to analytical,  pharmaco-
toxlcologlcal  and  clinical  standards and  protocols  In  respect  of 
the  testing of  proprietary medicinal  products  (O.J.  n·  L 147  of 
9.6.75) 
COMMISSION  DIRECTIVE  91/507/EEC  of  19  July  1991  modifying  the 
Annex  to Council  Directive 75/318/EEC  on  the approximation of  the 
laws  of  Member  States relating to analytical,  pharmaco-
toxlcologlcal  and  clinical  standards and  protocols  In  respect  of 
the  testing of medicinal  products  (O.J.  n·  L 270  of  26.9.91) 
COUNCIL  DIRECTIVE  83/570/EEC of  26  October  1983  amending 
Directives 65/65/EEC,  75/318/EEC  and  75/019/EEC  on  the 
approximation of  provisions  laid down  by  law,  regulation or 
administrative action relating to proprietary medicinal  products 
(O.J.  n·  L 332  of  28.11.83) 
COUNCIL  DIRECTIVE  87/19/EEC  of  22  December  1986  amending 
Directive 75/318/EEC  on  the  approximation of  the  laws  of  the 
Member  States relating  to analytical,  pharmaco-toxlcologlcal  and 
clinical  standards  and  protocols  In  respect of  the  testing of 
proprietary medicinal  products  (O.J.  n·  L 15  of  17.1.87) 
COUNCIL  DIRECTIVE  87/21/EEC of  22  December  1986  amending 
Directive 65/65/EEC  on  the  approximation of  provisions  laid down 
by  law,  regulation or  administrative action relating to 
proprietary medicinal  products  (O.J.  n·  L 15  of  17.1.87) 
COUNCIL  DIRECTIVE  87/22/EEC  of  22  December  1986  on  the 
approximation of  national  measures  relating  to the  placing on  the 
market  of  high  technology medicinal  products,  particularly  those 
derived  from  biotechnology  (O.J.  n·  L 15  of  17.1.87) 
- COUNCIL  DIRECTIVE  89/341/EEC  of  3  May  1989  amending  Directives 
65/65/EEC,  75/318/EEC  and  75/319/EEC  on  the  approximation of 
provisions  laid down  by  Jaw,  regulation or  administrative action 
relating  to proprietary medicinal  products  (O.J.  n·  L 142  of 
25.5.89) 
6' COUNCIL  DIRECTIVE  89/342/EEC  of  3  May  1989  extending  the  scope of 
Directives 65/65/EEC  and  75/319/EEC  and  laying  down  additional 
provisions  for  Immunological  medicinal  products consisting of 
vaccines,  toxins or  serums  and  allergens 
- COUNCIL  DIRECTIVE  89/343/EEC  of  3  May  1989  extending  the  scope of 
Directives 65/65/EEC  and  75/319/EEC  and  laying  down  additional 
provisions  for  radlopharmaceutlcals 
COUNCIL  DIRECTIVE  89/381/EEC of  14  June  1989  extending  the  scope 
of  Directives 65/65/EEC  and  75/319/EEC  on  the  approximation of 
provisions  laid  down  by  law,  regulation or  administrative action 
relating  to proprietary medicinal  products  and· laying  down 
special  provisions  for  medicinal  products derived  from  human 
blood or  human  plasma  (O.J.  n·  L 181  of  28.6.89) 
COMMISSION  DIRECTIVE  91/356/EEC  of  13  June  1991  laying  down  the 
principles and  guldel lnes of  good  manufacturing  practice  for 
medicinal  products  for  human  use  (O.J.  n·  L  193  of  17.7.91) 
COUNCIL  DIRECTIVE  92/25/EEC  of  31  March  1992  on  the  wholesale 
distribution of  medicinal  products  for  human.use  (O.J.  n·  L 113 
of  30.4.92) 
COUNCIL  DIRECTIVE  92/26/EEC  of  31  March  1992  concerning  the 
classification  for  the  supply of  medicinal  products  for  human  use 
co.J.  n·  L  113  of  30.4.92) 
COUNCIL  DIRECTIVE  92/27/EEC  of  31  March  1992  on  the  Iabeii lng  of 
medicinal  products  for  human  use  and  on  package  leaflets  (O.J.  n· 
L  113  of  30.4.92) 
COUNCIL  DIRECTIVE  92/28/EEC  of  31  March  1992  on  the  advertising 
of  medicinal  products  for  human  use  (O.J.  n·  L  113  of  30.4.92) 
COUNCIL  DIRECTIVE  92/73/EEC  of  22  September  1992  on  the 
·approximation 6f provisions  laid down  by  law,  regulation or 
administrative action  relating  to medicinal  products  and  laying 
down  additional  provisions on  homeopathic  medicinal  products 
(O.J.  n·  L 297  of  13.10.92) Annex 2 
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COMITE  DES  SPECIALITES  PHARMACEUTIQUES 
COMMITTEE  FOR  PROPRIETARTY  MEDICINAL  PRODUCTS 
President  I  Chairman  : 
Professore  Dull lo  POGGIOLINI 
VIce-Presidents I 
Deputy  Chairmen 
Dlrettore Generale  del  Servlzlo Farmaceutlco, 
Mlnlstero della Sanlta 
Vlale  della Clvllta Romana  7 
1-00144  Roma  EUR 
Tel.:  (39)(6)  592.58.63  I  592.55.25 
Telex:  625205  MINSAN  I 
Telefax:  (39)(6)  592.58.24 
M.  le  Professeur  Jean-Michel  ALEXANDRE  President  de  Ia  Commission 
d'enreglstrement  des  medicaments 
Mlnlstere  de  Ia  sante et  de  l'actlon 
humanltalre 
M.  Fernand  SAUER 
Direction de  Ia  Pharmacle  et  du  Medicament 
1,  Place  de  Fontenoy 
F~75700 Paris 
Tel.:  (33)(1)  40.56.47.09 
Telefax:  (33)(1)  40.56.53~55 
Chef  d'Unlte  "Prodults  pharmaceutlques" 
Commission  des  Communautes  europeennes 
Direction generale  du  Marche  lnterleur et  des 
Affalres  lndustrlelles 
111/C-3 
Te1.:(322)  295.51.80) 
secretariat du  Comlte  des speclalltes pharmaceutlques 1 
Secretariat of  the COmmittee  for  Proprietary Uedlclnal  Products 
Mrs.  Marie  C.  DONNELLY 
Telephone  :  (322)  - 296.03.32 
- 295.69.35 
Commission  des  Communautes  europeennes 
Direction generale  du  Marche  lnterleur  et  des 
Affalres  lndustrlelles 
Unite  "Prodults  pharmaceutlques" 
D.G.  II I  C 3- NERV  2/8 
Rue  de  Ia  Lol  200 
8-1049  8RUXELLES 
Telefax  :  296.15.20 
Telex  :  21.877  COMEU  8 LISTE  DES  MEUBRES  I  LIST  OF  MEMBERS 
a)  Representants  I  Representatives 
b)  Suppleants  I  Deputies  : 
BELGIQUE 
a)  M.  F.  GOSSELINCKX 
b)  M.  No~l  WATHION 
PANMABK 
a)  Mr.  Henning  HOVGAABD 
b)  Mrs.  Blrgltte KRISTENSEN 
DEUTSCHLAND 
- 2  -
Hoofdlnspecteur-Directeur 
Farmaceutlsche  lnspectle 
RIJksadmlnlstratlef  Centrum 
Vesal lusgebouw 
B-1010  Brussel 
Tel.:  (32)(2)  210.48.93 
Telex:  25.768.MVGSPF  B 
Telefax:  (32)(2)  210.48.80 
Farmaceutlsch  lnspecteur 
Farmaceutlsche  lnspectle 
(Idem) 
Tel.:  (32)(2)  210.48.96 
Reglstrerlngschef,  cand.  pharm. 
Sundhedsstyrelsen,  L~gemlddelafdellng 
FrederlkssundsveJ  378 
DK-2700  Br0nsh0J 
Tel.:  (45)  44-94.36.77 
Telex:  35333  IPHARM  OK 
Telefax:  (45)  44-94.02.37 
Afdellngsforstander  cand.  pharm. 
Sundhedsstyrelsen  (Idem) 
Tel.:  (45)  44-94.36.77 
a)  Prof.  Dr.  Alfred  G.  HILDEBRANDT  Leiter  des  lnstltuts  fUr  Arznelmlttel  des 
Bundesgesundheltsamtes 
SeestraBe  10 
D-1000  BerlIn 65 
Tel.:  {49){30)  4502.1  I  4502-1203 
Telex:  {2627)(17)  308062  BGESA  D 
Telefax:  (49)(30)  4502-1207 
b)  Frau Prof.  Dr.  med.  Ursula  GUNDERT-REMY  Lelterln der  Abtellung 
Experlmentelle und  kllnlsche Pharmakologle 
lm  lnstltut  fUr  Arznelmlttel  des 
Bundesgesundheltsamtes 
(Idem) 
Tel.:  (49)(30)  4502.1189 ESPAFlA  I  SPAIN 
a)  Dr.  F.  GARCIA  ALONSO 
b)  Ora.  Dolores  SANDOVAL 
FRANCE 
- 3  -
Dlreccl6n General  de  Farmacla  y  Productos 
Sanltarlos,  Mlnlsterlo de  Sanldad  y 
Con sumo 
Paseo del  Prado,  18- 20 
E-28014  Madrid 
Tel.;  (34)(1)  420.20.68 
Telex:  22.608 MSASS 
Telefax:  (34)(1)  420.32.17 
ou  420  10  42  (Min.  gen.) 
ou  420  11  67 
(questions  communaut.) 
Centro  Naclonal  de  Farmacoblologla 
MaJadahonda 
28220  Madrid 
Tel.:  (34)(1)  638.51.55 
Fax:  (34)(1)  638.06.13 
a)  M.  le  Professeur  Jean-Michel  ALEXANDRE  Direction de  Ia  Pharmacle  et  du 
Medicament 
Mlnlst6re  de  Ia  sant~ et  de  !'action 
human Ita Ire 
1,  Place de  Fontenoy 
F-75700  Paris 
Tel.:  (33)(1)  40.56.47.09 
Telefax:  (33)(1)  40.56.53.55 
b)  M.  le  Professeur  Jacques  DANGOUMAU  Agence  du  Medicament 
Mlnlstere des Affalres soclales,  de  Ia 
Sante et  de  Ia  VII le 
Tel.:  (33)  (1)  •••• 
(Mme.  Marle-Danlele campion- Mlnlstere des  Affalres soclales,  de  Ia  Sante et 
de  Ia  VIlle- AGENCE  DU  MEDICAMENT- DIRECTION  GENERALE- cellule Affalres 
Europeennes et  lnternatlonales,  143-145  Bd.  Anatole  France,  F-92200  SAINT--
DENIS,  Tel.  48  13  20  46,  Fax  48  13  20  03) 
M.  Patrick  LE  COURTOIS- procedures:  tel.  33  1  40.56.54.61,  fax  40  56  45  71) 
GREECE 
~) Professor  D.  VARONOS 
b)  Mme.  J.  YOTAKI 
Chairman  Registration Committee 
E.O.F. 
Mesoglon  284 
GR-155  62  Holargos 
Tel.:  (30)(1)  (E.O.F.)  6525194-5  I 
6525525-6-7 
resp.  (30)(1)  779.08.41  (University) 
Telefax:  (30)(1)  6545535 
Director  Pharmaceutical  Studies 
Division,  E.O.F. 
(Idem) 
Tel.:  (30}{1}  65  26  216 IRELAND 
a)  Dr.  Marie  BURNS 
b)  Dr.  Anthony  O'BRIEN 
ITALIA 
a)  Dott.  Romano  CAPASSO 
b)  Dr.  Marlsa  PAPALUCA 
LUXEMBOURG 
a)  Mme.  Jacqueline  GENOUX 
b)  Mme.  M.  BACKES 
- 4  -
Acting Medical  Director 
National  Drugs  Advisory  Board 
Charles Lucas  House 
63-64  Adelaide  Road 
Dub!  In  2 
Tel.:  (353)(1)  76.49.71-7 
Telex:  90542  NDAB  ~I 
Telefax:  (353)(1)  76.78.36 
Medical  Assessor 
National  Drugs  Advisory  Board  (Idem) 
Tel.:  (353)(1)  76.49.71- 7 
Cons!gl !ere M!nlsterlale 
Dlrezlone  Generale  Serv!zlo Farmaceutlco 
Mlnlstero della Sanlt! 
Vlale  delIa Clvllt! Romana  7 
1-00144  Roma  EUR 
Tel.:  (39)(6)  592.58.28 
Telefax:  (39)(6)  592.58.24 
Medical  Assessor 
Operative  Cente~ for  Community  Procedures 
Mlnlstero della San!t! 
VIa  della Sierra  Nevada  60 
1-00144  Roma  EUR 
Tel.:  (39)(6)  592.58.26 
Pharmaclen-lnspecteur,  Direction de  Ia 
sante 
Division de  Ia  Pharmacle  et  des 
Medicaments 
10,  rue  C.M.  Spoo 
L-2546  Luxembourg 
Tel.:  (352)  4.08.01 
Telex:  2546  SANTE  LU 
Telefax:  (352)  48.49.03 
Chef  de  Division  Pharmacle et Medicaments 
(Idem) NEDERLAND 
a)  Dr.  J.F.F.  LEKKERKEBKER 
b)  Dr.  W.F.  VAN  DEB  GIESEN 
PORTUGAL 
a)  Dr.  J.A.  ARANDA  da  SILVA 
b)  Prof.  Dr.  Jose  A.  MORAIS 
UNITED  KINGDOM 
a)  Dr.  Keith  H.  JONES 
b)  Dr.  David  JEFFERYS 
- 5  -
Internist,  Voorzltter  Col lege  ter 
beoordellng van  geneesmlddelen,  Mlnlsterle 
van  WelziJn,  Volksgezondheld  en  Cultuur 
Postbus  5811 
NL-2280  HV  RIJswiJk  (ZH) 
Tel.:  (31)(70)  340.79.11 
Telex:  31680  WVC  RW  NL 
Telefax:  (31)(70)  3~0.51.55 
Secretarls van  het  Col lege  ter  beoordellng 
van  geneesmlddelen  (Idem) 
Tel.:  (31}(70}  340.72.10 
Telex  and  Telefax  as  above 
President  of  the  Board  of  INFARMED 
Institute Naclonal  da  Farm!cla  e  do 
Medlcamento  - INFARMED 
Av.  Estados  Unldos  da  America,  37 
1700  Llsboa  I  Portugal 
Tel.:  (351)(1)  80  41  31 
Telex:  15655  MAS  P 
Telefax:  (351)(1)  8~ 80  331 
Ph.D.,  Assoc.  Prof.,  Unlversldade  de 
Llsboa,  Faculdade  de  Farmacla, 
Av.  das  Forcas  Armadas,  1600  Llsboa 
Tel.  793.30.64,  ext.  210 
Fax  793.77.03 
Director  Medicines  Control  Agency 
Department  of  Health 
Medicines  Control  Agency 
Market  Towers,  1  Nine  Elms  Lane 
London  SW8  5NQ 
Tel.:  (44)(71)  273.0100 
Telex:  883669  DHSSHQ  G 
Telefax:  (~~)(71}  273.0~93 
Head,  New  Drugs  and  European  Licensing 
Department  of  Health 
Medicines  Control  Agenci  (Idem) 
Tel.:  (44)(71)  273.0200 Annex 3 
Opinions of the CPMP in accordance with article 11 or 
article 12 of Directive 75/319/EEC (Pharmacovigilance) 
1991- 1992 COMMISSION 
OF  THE  EUROPEAN 
COMMUNITIES 
Brussels,  13  September  1989 
RESTRICTED 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
Pharmacovlgllance Opinion  No.6 relating  to  FLUNARIZINE 
Meeting  of  13  September  1989 
1.  By  letter of  28.2.89  the  competent  authority of  Denmark  requested  the 
CPMP  to give  an  opinion on  Slbellum  (Fiunarlzlne),  a  peripheral 
vasodilator. 
The  product  Is  currently authorized  In  Belgium,  Denmark,  the  Federal 
Republic of  Germany,  Greece,  Spain,  France,  Ireland,  lta)y,  Luxembourg, 
the  Netherlands,  Portugal. 
2.  The  Committee  considered  the  request  at  Its meeting of  11-12  July  1989 
and  Invited  the  company,  Janssen  Research  Foundation  (letter of  Belgium 
of  24  July  1989)  to supply additional  pertinent  Information. 
3.  The  Company's  written submission was  contained  In  a  letter of  31.8.89 and 
a  hearing before  the Committee  was  offered  (23.8.89). 
4.  During  the  hearing which  took  place  In  Brussels on  13th  September  1989, 
5  representatives of  the  company  attended and  made  a  presentation. 
5.  Having  taken  due  account  of  the adverse drug  reactions  reported,  the 
Committee  considered  that 
Flunarlzlne  should  be  contra-Indicated  In  patients with  a  history of 
extrapyramidal  symptoms,  Parkinsonism,  Alzheimer's  disease  and 
depression; 
a  special  warning  should  be  Included  In  any  Information,  mentioning 
that  'Fiunarlzlne may  Induce  extrapyramidal  and  depression  symptoms 
and  reveal  Parkinsonism.  It  should  be  used  with  caution especially  In 
the elderly'; 
alI  of  the  extrapyramidal  and  depressive  symptoms  should be  adeQuately 
mentioned  In  the  package  leaflet. 
6.  The  Indications,  especially central  and  peripheral  vascular  diseases, 
should  be  reviewed,  taking  Into account  the  risks. 
Provisional  oddr•••:  Rue  de  Ia Lot  200, 8- \04g  Brussela~ Telephone:  dtree\  line  23 •.•.• 1\ondord  23~  \1  11 
Telex:  COMEU  B 21877  Teleorophlc oddr•••:  COUEUR  Bru1aela COMMISSION 
OF  THE  EUROPEAN 
COMMUNITIES 
Brussels,  12  March  1991 
Pharmacovlgllance Opinion  No.  6/1  on  FLUNARIZINE 
Meeting  of  12th March  1991 
WHEREAS  the  Committee  for  Proprietary Medicinal  Products,  at  the  request  of 
Denmark  (22.2.89),  had  considered  the  adverse  event  profIle of  the  product 
Slbel lum  (Fiunarlzlne);  and  following  a  hearing  (13.9.89)  with  the  company 
Janssen  Research  Foundation,  had  adopted  an  opinion  (pharmacovlgl lance 
No.  6)  on  13th  September  1989.  · 
WHEREAS,  In  the opinion of  13~9.89,  the  Indications,  especially central  and 
peripheral  vascular  diseases,  were  to  be  reviewed  taking  Into  account  the 
risks.  Therefore  a  meeting  of  experts  took  place  on  2.7.90,  and  the 
rapporteur  (Belgium)  circulated  (29.10.90)  an  updated  assessment  report  and 
the  co-rapporteur  (Denmark)  also circulated an  assessment  report  (15.8.90). 
WHEREAS  the  product  Is  not  authorised  In  the  United  Kingdom; 
WHEREAS  the  company  circulated  (22.1.91)  additional  documentation  and  a 
proposal  for  the  summary  of  product  characteristics,  and  3  representatives 
attended a  hearing on,13.2.91 
1.  The  commIttee  consIders  that  for  the  concerned  Member  States,  on  the 
basis  of  current  data,  only  the  Indications  "prophylaxis  of  migraine  In 
patients  with  frequent  and  severe  attacks,  who  have  not  responded 
satlsfactorl IY  to  other  treatment  and/or  In  whom  other  therapy  has 
resulted  In  unacceptable  side-effects"  and  "symptomatic  treatment  of 
vestibular  vertigo,  due  to  diagnosed  functional  disorder  of  the 
vestibular  system"  may  In  principle be  accepted. 
2.  There  Is  a  need  for  confirmatory  extensive  controlled,  double  blind 
cl lnlcal  studies  In  order  to  support  the  benefit/risk  ratio  of 
flunarlzlne  In  both  these  Indications.  These  studies  should  refine  the 
optimal  dosage  regimen,  and  to  better  define  the  sequence  of  therapy 
e.g.  for  the  maintenance  treatment  of  migraine  prophylaxis.  In  those 
Member  States  where  these  Indications  are  not  currently  authorised, 
these  studies  would  have  to  be  assessed  before  such  an  Indication  could 
be  accepted. 
3.  A summary  of  product  characteristics  Is  In  annex. 
4.  The  company  Is  requested  to  estab I Ish  an  IntensIve  drug  monItor 1  ng 
program  In  order  to  estimate  the  Incidence  of  the  adverse  reactions, 
their  frequency  as well  as  the  population at  risk. 
5.  The  protocols  and  results of  the  on-going  trials  for  migraine  should  be 
submItted. 
6.  The  company  Is  requested  to  confirm,  In  writing,  that  the  company  has 
withdrawn  all  other  Indications  for  this product  In  all  Member  States. 
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Brussels,  11  September  1991 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
Pharmacovlgllance Opinion  No.  6/2 on  FLUNARIZJNE 
Meeting  of  11  September  1991 
WHEREAS  the  Committee  for  Proprietary Medicinal  Products,  at  the  request  of 
Denmark  (22.2.89),  had  considered  the  adverse  event  profile of  the  product 
Slbel tum  (Fiunarlzlne);  and  following  a  hearing  (13.9.89)  with  the  company 
Janssen  Research  Foundation,  had  adopted  an  opinion  (pharmacovlgl lance 
No.  6)  on  13th  September  1989. 
WHEREAS,  In  the opinion of  13.9.89,  the  Indications,  especially central  and 
peripheral  vascular  diseases,  were  to  be  reviewed  taking  Into  account  the 
risks.  Therefore  a  meeting  of  experts  took  place  on  2.7.90,  and  the 
rapporteur  (Belgium)  circulated  (29.10.90)  an  updated  assessment  report  and 
the  co-rapporteur  (Denmark)  also circulated an  assessment  report  (15.8.90). 
WHEREAS  the  product  Is  not  authorised  In  the United  Kingdom; 
WHEREAS  the  company  circulated  (22.1.91)  additional  documentation  and  a 
proposal  for  the  summary  of  product  characteristics,  and  3  representatives 
attended  a  hearing  on  13.2.91 
1.  The  committee  considers  that  for  the  concerned  Member  States,  on  the 
basis of  current  data,  only  the  Indications  "prophylaxis of  migraine  In 
patients  with  frequent  and  severe  attacks,  who  have  not  responded 
satlsfactorl ly  to  other  treatment  and/or  In  whom  other  therapy  has 
resulted  In  unacceptable  side-effects"  and/or  "symptomatic  treatment  of 
vestibular  vertigo,  due  to  diagnosed  functional  disorder  of  the 
vestibular  system"  may  ln.prlnclple  be  accepted. 
2.  There  Is  a  need  for  confirmatory  extensive  controlled,  double  blind 
clinical  studies  In  order  to  support  the  benefit/risk  ratio  of 
flunarlzlne  In  both  these  Indications.  These  studies  should  refine  the 
optimal  dosage  regimen,  and  to  better  define  the  sequence  of  therapy 
e.g.  for  the  maintenance  treatment  of  migraine  prophylaxis.  In  those 
Member  States  where  these  Indications  are  not  currently  authorised, 
these  studies would  have  to  be  assessed  before  such  an  Indication  could 
be  accepted. 
3.  A summary  of  product  characteristics  Is  In  annex. 
4.  The  company  Is  requested  to  establish  an  Intensive  drug  monitoring 
program  In  order  to  estimate  the  Incidence  of  the  adverse  reactions, 
their  frequency  as well  as  the  population at  risk. 
5.  The  protocols  and  results of  the  on-going  trials  for  migraine  should  be 
submitted. 
6.  The  company  Is  requested  to  confirm,  In  writing,  that  the  company  has 
withdrawn  all  other  Indications  for  this product  In  all  Member  States. 
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Brussels,  13  December  1989 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
Pharmacovlgllance opinion  No ..  8  on  GLAFENINE  and  FLOCTAFENINE 
1.  In  March_1989,  the  Belgian crathorltles  reQuested  the  Committee  for 
Proprietary Medicinal  Products,  In  accordance with  Article  12  of 
Directive 75/319/EEC,  to give  a  pharmacovlgllance opinion on  Glafenlne 
and  Floctafenlne. 
2.  During  Its meeting on  14-15  November  1989  and  on  12-13 December  1989,. 
the  Committee  considered  the  spontaneous  pharmacovlgl lance  data which 
had  been  forwarded  by  the  Member  States,  and  agreed: 
I)  The  following  amendments  should  be  Inserted  In  the  Summary  of 
Product  Characteristics for  Glafenlne: 
Under  'Therapeutic  Indications':  Glatenlne  Is  reserved  as-a 
second  line  treatment,  to  be  used only  when  other  analgesic 
products  are  Inappropriate. 
Under  'Contra-Indication',  the  following  to  be  added:  Any  known 
hypersensitivity  to Glafenlne  and  Its derivatives  Is  an  abso)ute 
contra-Indication  to treatment. 
Under  'Particular  precautions  for  use': 
- Glafenlne  must  be  stopped  Immediately  as  soon  as  the  first 
sign of  hypersensitivity becomes  evident; 
-repeat prescriptions should  be  avoided; 
- Glafenlne  should  not  b~ given  to patients  for  whom  It  Is  not 
prescribed; 
- It  Is  necessary  to  drInk  cop lous  1-y  In  order. to  reduce  .the  rIsk 
of  lntrarenal  crystallization.· 
II)  The  supply  of  Glafenlne  should  be  subject  to  non  renewal ·medical 
prescription  (List  1  of  the  Counci I  of  Europe). 
3.  On  the  basis  of  the  pharmacovigl lance  data  currently  aval table,  the  CPMP 
considers  that  Floctafenlne  appears  to present  a  lower  incidence  of 
side-effects  than  Glafenine.  With  the  exception of  intrarenal 
crystal I ization,  the  risk  profile  however  seems  similar. 
The  ADR  of  both  Glafenine  and  Floctafcnine  would  continue  to  be 
monitored  and  the  position  would  be  later  reviewed  by  the  CPMP,  If 
necessary. 
·---~-··----
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Brussels,  13  February  1991 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
Pharmacovlgllance Opinion  No.  8/1  relating  to GLAFENINE 
Meeting of  13  February  1991 
WHEREAS  t~e committee  for  Proprietary Medicinal  Products  adopted  an  opinion  ' 
on  GLAFENINE  on  13.12.1989; 
WHEREAS,  In  the short  time  since  the  adoption of  that opinion,  only  limited 
resu  1 ts  have  been  observed  so  far;  whereas  no  unexpected  data  have  been 
submitted  to  the Committee  since December  1989: 
1.  The  Committee  considers  that  the  opinion  of  13.12.1989  remains 
unchanged. 
2.  In  accordance  with  the  opinion  of  13.12.1989,  the  Committee  wishes  to 
continue  Its survel I lance  particularly with  regard  to adverse  reactions, 
and  therefore  reQuests 
-the marketing  authorisation  holders  to prepare  a  safety update,  taking 
account  of  global  data,  especially  Identifying  the  data  for  the  year 
1990; 
-the  Member  States  upon  whose  territory  this  product  Is  marketed,  to 
compl le  and  report  on  the up-to-date situation. 
I· 
3.  The  Committee  will  consider  this  Information  at  Its  meeting  In  June 
1991,  following  which  Its opinion would  be  finalised. 
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Brussels,  14  January  1992 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
Pharmacovlgllance opinion No.  8/2 on  GLAFENINE 
Brussels,  14  January  1992 
WHEREAS,  In  March  1989,  the  Belgian competent  authorities  requested  the 
committee  for  Proprietary Medicinal  Products,  In  accordance with Article  12 
of  Directive 75/319/EEC,  to give  a  pharmacovlgllance opinion on  Glafenlne, 
a  peripheral  analgesic,  on  which  a  number  of side-effects,  particularly 
anaphylactic  reaction,  and  lntrarenal  crystal I lsatlon had  been  reported. 
France  and  the  Netherlands  agreed  to act  as  rapporteurs; 
WHEREAS  Glafenlne  was  authorised,  at  that  time,  In  Belgium,  Spain,  Greece, 
France,  Italy,  the  Netherlands  and  Portugal,  as well  as  In  approximately  75 
countries outside  the  European  Community.  The  company  had  withdrawn  the 
product  from  the  German  market  In  August  1983,  and  no  application had  been 
made  In  Denmark,  Ireland and  the  United Kingdom; 
WHEREAS,  during  Its meeting on  14-15  November  1989  and  on  12-13 December 
1989,  the  Committee  considered  the  spontaneous  pharmacovlgllance  data  which 
had  been  forwarded  by  the  Member  States,  and  agreed  a  number  of  safeguard 
measures,  Including  I lmltlng  the  supply of  Glafenlne  to non  renewal  medical 
prescription  (List  1 of  the  Council  of  Europe),  and  amendments  In  the 
summary  of  Product  Characteristics: 
Under  'Therapeutic  Indications':  Glafenlne  Is  reserved as  a  second 
I lne  treatment,  to  be  used  onlY  when  other  analgesic  products  are 
Inappropriate .. 
Under  'Contra-Indication':  the  following  to be  added:  Any  known 
hypersensitivity  to Glafenlne  and  Its derivatives  Is  an  absolute 
contra-Indication  to  treatment. 
Under  'Particular  precautions  for  use': 
- Glafenlne must  be  stopped  Immediately  as  soon  as  the  first  sign of 
hypersensitivity becomes  evident; 
-repeat prescriptions should  be  avoided; 
- Glafenlne  should  not  be  given  to patients  for  whom  It  Is  not 
prescribed; 
- It  Is  necessary  to drink  copiously  In  order  to  reduce  the  risk of 
lntrarenal  crystal llzatlon. 
WHEREAS,  In  December  1990,  the Belgian  competent  authorities withdrew  the 
marketing  authorisation  In  Belgium  for  Glafenlne~  Luxembourg  mutually 
recognised  this action and  also withdrew  the marketing  authorisation; 
WHEREAS,  at  the meeting of  13  February  1991,  the  Committee  reissued  Its 
opinion  and  Invited  the marketing  authorisation holders  to prepare  a  safety 
update,  taking  account  of  global  data,  especially  Identifying  the  data  for 
the  year  1990,  and  In  order  to  continue  Its survel I lance,  particularly with 
regard  to  adverse  reactions,  requested  the  Member  States upon  whose 
territory this  product  was  marketed  to compl le  and  report  on  the up-to-date 
situation; 
Provisional  address:  Rue  de  Ia Lol  200,  B- 1049  Brussela.  Telephone:  direct  line  23 ••..• 1tandard  23~  11  11 
Telex:  COMEU  B 21877  Telegraphic  addreea:  COUEUR  Brusaela - 2  -
WHEREAS,  In  May,  the  company  Roussei-Uclaf  submitted  a  safety update,  which 
was  further  elaborated  In  September  1991; 
WHEREAS  the  competent  authority  In  the  Netherlands  had  Initiated a  case-
cohort  epidemiological  study,  focussing  on  anaphylactic  reaction only.  The 
final  results of  this study were  circulated to all  members  of  the Committee 
on  13  November  1991,  and  to the  company  Roussei-Uclaf; 
WHEREAS,  at  the meeting on  12  December  1991,  the  Committee  considered  the 
submissions of  May,  September  and  November  1991,  and  the  company  Roussei-
Uclaf  presented for  a  hearing; 
WHEREAS  the matter  was  further  considered at  a  meeting of  the  Committee  on 
14  Janu~ry 1992,  when  the  company  submissions of 5.12.91  and  10.1.92 were 
also  reviewed; 
1.  The  Committee  considers  that  the signal  first  Identified  In  spontaneous 
survel 1 lance  has  been  confirmed  by  the  Dutch  epidemiological  study,  and 
that  the  risk of  anapha'lactlc  reaction with Glafenlne  Is  higher  than  for 
other  analgesics.  Given  the seriousness of  the  reaction,  the 
benefit/risk ratio of  tne  product  Is  considered  negative  and  the 
marketing  authorization should  be  withdrawn. 
2.  France  and  Portugal  do  not  concur  with  the scJentJfJc assessment  of  the 
Committee.  They  do  not  share  the  conclusions of  the  Dutch 
epidemiological  study  and  therefore consider: 
-there  Js  no  new  Information available, 
- Glafenlne,  aside  from  anaphylactic  reaction,  has  less of  some  other 
side effects  than other  analgesic/antiinflammatory compounds. 
Therefore  the  product  Is stl II  considered  to  have  a  favourable 
benefit/risk ratio when  used  as a  second  line  treatment  In  patients 
where  other  analgesics are  Inappropriate. 
3.  In  accordance with  Article  14(3)  of  Directive 75/319/EEC,  as  amended  by 
Directive 83/570/EEC,  all  Member  States shal I  Inform  the  Committee, 
within 60  days,  on  what  action  they  have  taken on  the  Committee's 
opinion. 
4.  In  accordance with Article  33(3)  of  Directive 75/319/EEC,  as  amended  by 
Directive 89/341/EEC,  Member  States shall  forthwith  bring  to  the 
attention of  the  World  Health Organisation any  action which  may  affect 
the  protection of  public health  In  third countries,  with  a  copy  to  the 
Committee. COMMISSION 
OF  THE  EUROPEAN 
COMMUNITIES 
Brussels,  11  September  1991 
Rev.  1 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
Inhaled  fenoterol  In  the  treatment  of  chronic  and  acute  asthma 
Pharmacovlgllance Opinion  No.  10 
On  27.3.1991,  Italy  circulated  a  Pharrnacovlgl lance  request  to  alI  Member 
States  regarding  Fenoterol,  and  Its authorization status. 
The  marketing  authorization  holder  In  the  Netherlands  and  In  Italy, 
Boehringer  ingelhelm,  proposed  (5.7.1991)  an  alteration  to  the  prescribing 
Information,  which  raised  a  number  of  questions  with  regard  to  the  use  of 
fenoterol  and  the  appropriate  prescribing  Instructions  for  the  product. 
Germany,  In  July  1991,  requested  the  Committee  for  Proprietary  Medicinal 
Products  for  an  opinion,  In  accordance  with  Article  12  of  Directive 
75/319/EEC.  Germany  and  Italy  have  agreed  to act  as  rapporteurs. 
The  authorisation  holder  was  Invited  to  present  an  overview  of  the 
benefit/risk profile of  the  product  with  particular  regard  to 
*  the  use  of  fenoterol  In  the  treatment  and  prophylaxis  of  asthma  and  In 
comparison with other  treatments; 
*  the  Implications  of  reduced  dosage,  an  alteration of  Indications  and/or 
the  method  of  administration on  the  benefit/risk prof! le  of  the  product. 
A  preliminary  discussion  between  the  company,  the  Efficacy  Working  Party 
and  some  members  of  the  Pharmacovlgl lance  Working  Party  tool<  place  on 
27.8.91,  with  a  report  to  the  CPMP  In  September  1991. 
In  september  1991,  the  CPMP  considered  the  report  (I I 1/3520/91). 
1.  The  Comml ttee  considers  that  In  the  light  of  the  lnformat ron  ava 1  I  able 
the  summary  of  product  characteristics  (article  4(a)  of  Directive 
65/65/EEC)  should  be  amended,  particularly  In  regard  to: 
A.  lndlcat Ions 
A.1  100  meg/puff 
a)  Symptomatic  treatment  of  acute  asthma  episodes 
b)  Prophylaxis of  exercise  Induced  asthma 
c)  Symptomatic  treatment  of  bronchial  asthma  and  other  conditions 
with  reversible  airways  narrowing  e.g.  chronic  obstructive 
bronchitis.  Concomitant  anti-Inflammatory  therapy  should  be 
considered. 
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A.2  200  meg/puff 
The  Indications  detailed  In  A.1,  when  not  adequately  control led  by 
the  use  of  Berotec  100  meg/puff  as  part  of  an  appropriate 
therapeutic plan. 
B.  posage  regimen  (applies  for  both  formulations) 
a)  Acute  asthma  episodes 
1  puff  of  Berotec  Is  sufficient  for  prompt  symptom  relief  In  many 
cases.  In  more  severe  cases,  If  breathIng  has  not  not I  ceab I  y 
Improved  after  5  minutes,  a  second  dose  may  be  taken. 
If  an  attack  has  not  been  ielleved  by  2  puffs,  further  puffs  may 
be  required.  In  these  cases,  patients  should  consult  the  doctor 
or  the  nearest  hospital  Immediately. 
b)  Prophylaxis of exercise  Induced  asthma 
1-2 puffs  for  each  admlnlstratlon,·UP  to a  maximum  of  8  puffs  per 
day. 
c)  BronchIa I  asthma  and  other  condl t Ions  wl th  revers lble  aIrways 
narrowing 
If  repeated  dosing  Is  required,  1-2  puffs  for  each 
administration,  up  to a  maximum  of  8  puffs  per  day. 
c.  precautions/Warnings 
Prolonged  use:  -On  demand  treatment  (symptom  oriented)  may  be 
preferable  to  regular  use. 
-Particularly  In  the  case  of  regular  use,  patients 
should  be  re-evaluated  for  the  addition  or  the 
Increase  of  anti-Inflammatory  therapy  (e.g.  Inhaled 
corticosteroids)  to control  airway  Inflammation  and 
.to prevent  long  term  damage. 
2.  The  company  Is  requested  to  submit  an  application  for  the  100  meg/puff 
formulation  In  alI  Member  States. 
3.  The  protocols,  results  and  timetable  of  on-going  studies  should  be 
submitted  as  soon  as  aval lable. - WHEREAS, 
competent 
requested 
regarding 
COMMISSION 
OF  THE.  EUROPEAN 
COMMUNITIES 
Brussels,  16  October  1991 
COMMITTEE  FOR  PROPRIETARY  MEDICINAt  PRODUCTS 
Meeting of  16  October  1991 
Position Statement  on  TRIAZOLAM 
In  accordance  with  Article  11  of  Directive  75/319/EEC,  the 
authorities  In  France  (2.10.91)  and  In  the  Netherlands  (4.10.91) 
the  opinion  of  the  Committee  for  Proprietary  Medlclna!  Products 
the  medicinal  product  HALCION(R)  (trlazolam); 
WHEREAS  the  company,  Upjohn,  circulated  a  revised  Protocol  321  to  all 
Member  States; 
WHEREAS  the  medicinal  product  containing  0.25  mg  and  0.125  mg  trlazolam  Is 
.authorised  In  Belgium,  Denmark,  Germany,  Spain,  Greece,  France,  Ireland, 
Italy,  Luxembourg,  the  N-etherlands,  Portugal  and  the  United  Kingdom.  The 
authorisation  of  the  medicinal  product  was  suspended  on  2.10.1991  In  the 
United  Kingdom  Initially  for  a  period  of  3  months  (which  may  be  renewed) 
and  procedures  to  revoke  that  authorisation  have  been  Initiated. 
WHEREAS  In  response  to questions  raised  by  Member  States,  the  authorisation 
holder  Upjohn  submitted  a  large  amount  of  Information  to  al 1  Member  states 
on  11 . 10. 91 . 
WHEREAS  the  Committee  considered  this  medicinal  product  at  Its  meeting  on 
16.10.91,  at  which  time  the  company  presented  for  a  hearing. 
WHEREAS  the  United  Kln~dom attended  the  meeting  and  presented  the  factual 
basis  tor  Its  action,  however  In  order  not  to  prejudice  the  UK  appelate 
procedure,  It  did  not  participate  In  the  discussions  leading  to  this 
Position  Statement,  which  does  not  Include  the  United  Kingdom. 
1.  Given  the  large  volume  of  Information  supplied  on  11.10.91,  the 
Committee  considers  It  necessary  to  review  these  data,  as  well  as  data 
In  the  appl !cation  dossier  and  Information  from  pharmacovlgi lance. 
Rapporteurs  have  been  appointed  and  wl  I I  report  In  December  1991. 
2.  Upon  preliminary  conslderat ion  of  the  avai lal">le  data,  evidence  of  new 
risks  at  recommended  doses  do~s not  seem  to  be  available. 
3.  The  Information  on  the  only  aval lable  presentations  (0.25  mg  and 
0.125  mg)  should  be  Immediately  strengthened  {see  Annex). 
4.  To  emphasize  that  the  product  Is 
proposed  Introducing  small  pack 
smal I  packs  (not  more  than  7 
Immediately. 
for  short-term  use,  the  company  has 
sizes.  The  Committee  considers  that 
tablets)  should  be  made  available 
5.  The  company  has  accepted  to  perform  an  extensive  pin-European  control led 
comparative  post-marketing  safety  and  efficacy  study  immediately,  ahd  a 
draft  protocol  should  be  submitted  to  the  Committee  before  December 
199, . 
6.  The  Committee  wi  II  formulate  Its  op1n1on  In  December  1991,  taking  Into 
account  the  ful I  review of  alI  existing data. 
~ue  de  Ia  Lei  ZOO,  8- 1049  6ruoseos 
telephone':  direct  line  2~ ••..•  standard  2~!>  11  11  Telex:  C().I~U  B  21e77  Teleorophic  addreu:  C().I~U~  Brusuos ANNEX 
Indication 
add:  Trlazolam  Is  only  Indicated  when  the  sleeping  disorder  Is  severe, 
dlsabl lng  or  causing  extreme distress. 
Duration of use 
trlazolam  should  not  be  used  for  more  than  2-3  weeks,  and  treatment 
thereafter  requires  a  ~omplete re-evaluation of  therapy. 
Posology 
The  lowest  effective  dose  should  be  used.  For  many  patients  a  dose  of 
0.125  mg  Immediately  before  retiring  may  be  sufficient.  A  dose  of 
0.25  mg  should  not  be  exceeded. 
For  elderly,  debi I itated 
I iver/kldney  function,  the 
retIrIng. 
patients  and  patients 
dose  should  not  exceed 
with  disturbed 
0.125  mg  before 
Safety  and  efficacy of  trlazolam  have  not  been  establ lshed  for  patients 
younger  than  18. 
Warning: 
Triazolam  should  not  be  used  in  patients  with  any  major  psychiatric 
disorders. 7 
WHEREAS, 
competent 
requested 
regarding 
COMMISSION 
OF  THE  EUROPEAN 
COMMUNITIES 
Brussels,  11  December  1991 
---- COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
T R I  A Z 0  L A M 
Pharmacovlgllance Opinion  No.  11 
In  accordance  with  Article  11  of  Directive  75/319/EEC,  the 
authorities  In  France  (2.10.91)  and  In  the  Netherlands  (4.10.91} 
the  opinion  of  the  Committee  for  Proprietary  Medicinal  Products 
the medicinal  product  HALCION(R)  (trlazolam); 
WHEREAS  the  medicinal  product  containing  0.25  mg  and  0.125  mg  trlazolam  Is 
authorised  In  Belgium,  Denmark,  Germany,  Spain,  Greece,  France,  Ireland, 
Italy,  Luxembourg,  the  Netherlands,  Portugal  and  the  United  Kingdom.  The 
authorisation  of  the  medicinal  product  was  suspended  on  2.10.1991  In  the 
United  Kingdom  Initial IY  for  a  period  of  3  months  (which  may  be  renewed) 
and  procedures  to  revoke  that  authorisation  have  been  Initiated.  WHEREAS 
the  United  Kingdom  attended  the  meeting;  however  In  order  not  to  preJudice 
the  UK  appelate  procedure,  It  did  not  participate  In  the  discussions 
leading  to this Opinion; 
WHEREAS  In  response  to questions  raised by  Member  States,  the authorisation 
holder  UpJohn  submitted  a  large  amount  of  Information  to  alI  Member  states 
on  11.10.91,  and  presented  for  a  hearing on  16.10.91. 
WHEREAS  the  Committee  considered  this  medicinal  product  at  Its  meeting  on 
16.10.91,  at  which  time  the  company  presented  for  a  hearing; 
WHEREAS,  given  the  large  volume  of  Information  suppl led  on  11.10.91  and  In 
the  I lght  of  the  hearing,  the  Committee  considered  It  necessary  to  review 
these  data,  as  well  as  data  In  the  application dossier  and  Information  from 
pharmacovlgllance.  Rapporteurs  were  therefore appointed. 
WHEREAS,  the  Committee  considered  the  report  of  the  rapporteurs  on 
11.12.91,  at  which  time  the  company  presented  again  for  a  hearing  and  made 
further  proposals  (11.12.91); 
1.  The  Committee  confirms  the  safeguard  measures  as  Indicated  In  Its 
position  statement  of  16.10.1991,  particularly  with  regard  to  the 
maximum  dosage  of  0.25  mg,  the  narrow  and  very  precise  Indications,  as 
well  as  contra-Indications,  for  this  product,  the  absolute  Importance 
of  short  term  usage  (not  more  than  10  days),  which  has  been  reinforced 
by  the  Introduction of  smal I  pack  sizes  In  alI  Member  States. 
2.  In  order  to  complete  the  excellent  work  done  by  the  rapporteurs,  the 
CommIt tee  has  InvIted  them  to  fu I I  y  assess  the  reI at I  ve  rIsk/benefIt 
ratio of  all  short  acting hypnotics. 
3.  The  safety  In  cl lnlcal  use  of  alI  hypnotics  wl  I I  continue  to  be 
monitored  by  the  Committee. 
Rue  de  Ia Lol  200,  B- 104~ Brueeele. 
Telephone:  direct  line  23 ...•.  etondord  23~ 11  11  Telex:  COMEU  B 21877  Telegraphic  a~u•e••  COUEUR  Bruseele COMMISSION 
OF  THE  EUROPEAN 
COMMUNITIES 
Brussels,  4  December  1992 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
Pharmacovlgllance Opinion  No.  12  on  NOSCAPINE 
Meeting of  4  December  1992· 
In  November  ~989,  the  competent  authorities of  the  Netherlands  Informed  the 
Committee  for  Proprietary Medicinal  Products  (CPMP)  of  a  publication  which 
suggested  a  possible  association  of  noscaplne,  an  alkaloTd  of  opium,  with 
polyploidy.  The  matter  was  referred by  the  CPMP  to  the  Safety Working  Party 
which  was  requested  to  compile  and  consider  all  up-to-date scientific data. 
WHEREAS,  the  Safety  Working  Party  considered  the  question  In  January  and 
May  1990,  and  Indicated  the  need  for  further  Information  on  the  mutagenic 
and  genotoxlc  potential  of  noscaplne;  whereas,  In  October  1990,  the 
company,  Beecham  Research,  supplied  additional  Information,  which  was 
considered; 
WHEREAS,  In  March  1991,  the  United  Klngdom~greed to act  ~s rapporteur,  and 
alI  assessment  reports  as well  as  the  authorisation status of  the  substance 
In  all  Member  States  were  reviewed.  An  expert  report  was  prepared  and 
submitted  to  the  CPMP  In  May  1991,  as  well  as  a  paper  on  'Noscaplne  Induced 
polyploidy  In  vitro'. 
The  UK  assessment  concluded  that  for  anaesthetic  products,  such  as  Omnopon 
which  was  marKeted  In  UK,  the  noscaplne  component  carried  no  additive 
benefit  In  the  product.  It  was  the  UK  position  that  for  such  products  there 
was  no  justification  for  tolerating  any  risk,  even  If  this  Is  largely 
derivative  I.e.  from  In  vitro data.  This  I Imitation was  considered  to  apply 
especially  to  the  women  of  reproductive capacity.  Therefore,  In  the  UK,  the 
legal  status  of  noscaplne  containing  anti-tussive  medicinal  products  was 
changed  to  "prescription only  medicine  (POM)"  from  General  Sales  List  (for 
maximum  dose  15  mg,  dally  Intake  5  mg)  on  July  20th,  1992.  As  a  result  of 
act Ions  taken  hy  the  manufacturer,  noscaplne  Is  no  ronger  a  component  In 
anti-tussive medicinal  products on  the  UK  marKet  . 
In  the  opinion  of  some  Member  States,  exemplified  by  DenmarK,  where 
noscapine  containing  anti-tussive  products  are  available  without  .a 
prescription  (OTC),  the  In  vitro  data  was  not  convincing  that  a  potential 
hazard  existed  with  respect  to  human  safety,  and  did  not  change  the 
marKeting  situation.  The  results  of  further  elucidation  of  the  potential 
genotoxlclty,  studies  of  which  were  In  process  In  Sweden,  were  awaited 
Instead. 
This  new  material  became  available  at  the  beginning  of  1992  and  was 
evaluated  In  an  extensive  report  by  the  Swedish  Medical  Products  Agency. 
This  report  described polyploidy  In  general  and  the  available  lnformat ion 
to  elucidate  the  potential  genotoxiclty  and  reproductive  toxicity  of  the 
substance  and  mentioned  the  Information  on  carcinogenic activity. 
---------------------- --------~R~u-e_d_e~l-o~l-o~i~20~0-.~B~-~~~04~9~B~r-us-s~el~s-.----------------------------­
Tet•phone:  direct  1 jnf'  2~  .  otondord  2J~  11  II  Telex:  COUEU  B  21877  lelegropnic  address:  COUEUR  Bru<sels - 2  -. 
The  assessment  concluded  that  the  only  reliable  results  so  far  that 
Indicated  a  relevant  genotoxlc  potential  of  noscaplne  was  the  demonstrated 
spindle  damaging  effect  and  the  polyploid/aneuploid  Inducing  capacity  at 
high  concentrations  In  yltro.  There  were  eQuivocal  results  concerning  a 
clastogenlc  activity  In  yltro.  However,  It  had  been  clearly  shown  that 
noscaplne dld'not  Induce  gene  mutations  In  yltro and  was  without  an  aneugen 
and  clastogenlc  activity  In  ylyo.  Based  on  these  conclusions  and  the  low 
systemic  exposure  In  man,  the  Swedish  Medical  Products  Agency  did  not 
consider  It  justified to undertake  restrictive regulatory action on  the  use 
of  noscaplne  In  women  of  childbearing  age,  or  on  Its  general  use  by  making 
It  aval lable  on  prescription only. 
The  CPMP  concluded  that  the  data  presented  and  the  assessment  of  safety 
performed  did  not  present  significant  Indications  of  potential  hazardous 
effects  In  man  from  the  use  of  the  substance  as  an  ant 1-tuss I  ve.  The 
absence  of  any  reported  hazards,  despite  the  extensive  use  for  decades  of 
noscaplne  In  clinical  practice was  also noted.  Furthermore,  pharmacoklnetlc 
studies  demonstrated  a  very  low  systemic  exposure  In  man  after  taking 
therapeutic doses  of  the  active substance  In  anti-tussive preparations. 
In  conclusion  the  CPMP  does  not  propose  restrictions at  this  time  for  anti-
tussive  medicinal  products  containing  noscaplne,  although  the  different 
pattern of  dosa~e and  supply of  such antl-tusslves across  the  Community. Annex 4 
Multi-state procedures which have been completed Much  1993 
aM:lETED MJ.TI-SIAJE ~ 
f.UT- autor isat ion  REf( 1)  - refusal /wi thdra.a.a.l  CR  - country of origin  * - not  concerned 
PAYS  I  COUNTRIES 
I  I  I  I  I  I  I  I  I  I  I  I  1---
1  M:DIC'J.tw£NT/  I  BE·  I  [l(  I  t:E  I  ESP  I  FR  I  ffi  I  IRL  I  IT  I  LLD<  1·  NL  I  ro  I  U< 
I  Q:>inion  No./Date  I  I  I  I  I  I  I  I  I  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  1---
IPeppennint oi I  I  REF  I  REF  I  REF  . I  REF  I  f.UT  I  REF  I  *  I  REF  I  REF  I  REF  I  *  I  CR 
176,  23.11.88  123.12.88109.12.88110.01.89121.12.88115.6.89  122.12.881  128.12.88129.12.88112.12.881  I 
I  I  I  I  I  I  I  I  I  I  1---
1  Cefurox  irre  *  *  I  fVT'  I  *  I  *  I  *  I  *  I  *  I  *  I  fVT'  I  *  I  ffi 
In, 14.9.88  109.03.891  I  I  I  I  I  117.03.891  I 
I  I  I  I  I  I  I  I  I  I  1---
IRecarb.l-lrra.n Grcwth Honn.  *  *  I  IUf  I  IUf  I  f.UT  I  *  I  f.UT  I  ffi  I  *  I  *  I  *  I  IUf 
178,  15.2.89  122.02.89116.04.89103.04.891  123.02.891  I  I  I  110.11.89 
I  I  I  I  I  I  I  I  I  I  1---
1  Enoxirrone  *  *  I  IUf  I  AA  I  at  I  *  'I  *  I  •  I  J!UT  I  J!UT  I  *  I  * 
179,  14.12.88  125.08.89121.12.881  I  I  I  121.06.89107.06.891  I 
I  I  I  I  I  I  I  I  I  I  1---
IDisopyranide  f.UT  J!UT  I  J!UT  I  *  I  ffi  I  *  I  f.UT  I  *  I  *  I  J!UT  I  *  I  /IUT 
180,  14.12.88  11.04.90 10.01.89125.04.891  I  ·1  120.04.891  I  120.02.891  101.03.89 
I  I  I  I  I  I  I  I  I  I  I  1---
IPodophyllotoxin  *  I  *  I  *  .  I  *  I  JUT  I  *  I  *  I  /IUT  I  /IUT  I  ffi  I  *  I  /IUT 
181,  14.12.88  I  I  I  105.08.881  I  128.12.88122.02.891  I  118.01.89 
I  I  I  I  I  I  I  I  I  I  I  1---
15-asa  I  J!UT  I  ffi  I  /IUT  I  *  I  *  I  *  I  PUT  I  /IUT  I  J!UT  I  *  I  *  I  /IUT 
182,  14.12.88  111.04.901  113.02.891  I  I  102.02.89128.12.88122.2.89  I  I  124.08.90 
I  I  I  I  I  I  I  I  I  I  I  I  1---
1  lora  tad  i ne  I  ffi  I  *  I  J!UT  I  *  I  ·  *  I  PUT  I  *  I  *  I  *  I  J!UT  I  *  I  * 
183,  15.2.89  I  I  125.08.891  I  125.10.881  I  I  120.03.891  I 
I  I  I  I  I  I  I  I  I  I  I  I  1---
IGaTeprost  I  /IUT  I  *  I  •  I  *  I  *  I  *  I  *  I  *  I  /IUT  I  /IUT  I  *  I  ffi 
184,  13.9.89  107.02.901  I  I  I  I  I  I  117.11.89116.10.891  I 
I  I  I  I  I  I  I  I  I  I  I  I  1---
ISalbutaTOI  I  *  I  *  I  J!UT  I  •  I  *  I  *  I  *  I  *  I  J!UT  I  *  I  *  I  ffi 
188,  15.2.89  I  I  I 16.06.891  I  I  I  I  117.11.891  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  1---
( 1)  An  applicant rray  subs~ent  ly appeal  the limber State ruling,  using national  proced.lres. Mirch  1993 
roe.EJB) M.JJI-STAJE  PRXHI..RES 
IUT- autorisation  REf(1)  - refusal/withdra.o.a.l  m- country of origin  *-not concerned 
I  I 
I  PAYS  I  COUNTRIES  I  -------------------1  I  I  I  I  I  l  I  I  I  I  I  I 
MDICM£NT/  I  BE  I  [l(  I  a:  I  ESP  I  FR  I  ffi  I  IRL  I  IT  I  LU<  I  NL  I  ro  I  U<  I 
Q:>inionNo./Date  I  I  I  I  I  I  I  I  I  I  I  I  I.  -------------------1  I  I  I  I  I  I  I  I  I  I  I  I 
ITerodi I ine 1-CI  I  ~. I  *  I  ~ I  PUT  I  REF  I  *  I  *  I  REF  I  IUT'  I  *  I  *  I  CR  I 
163,  15.6.88  105.01.891  113.12.89117.06.88115.11.881  I  113.07.88119.08.881  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  I  I 
feet i r i z i ne  I  CR  I  PUT  I  *  I  *  I  *  I  flUT  I  IUT'  I  ,AUT  I  *  I  IUT'  I  *  I  PUT  I 
164,  14.4.88  I  128.04.881  I  I  101.03.88115.08.88113.03.891  125.08.881  116.09.881 
I  I  I  I  I  I  I  I  I  I  I  I 
· 1/mi no acids  I  lilT  I  *  I  AA  I  J1UT  I  CR  I  *  ·  I , REF  I  AA  I  AA  I  IUT'  *  J1UT  I 
165,  13.4.88  124.05.881  107.02.00116.06.881  I  109.12.87108.02.89111.05.88112.09.88  11.10.891 
I  I  I  I  I  I  I  I  I  .  I  I  I 
IDextrose  I  IUT'  I  IUT'  I  REF  I  *  I  REF  I  PUT  I  IUT'  I  *  I  ~ I  J1UT  *  CR  I 
166,  17.2.88  115.09.89125.04.88113.02.891  110.07.89101.08.88103.02.891  130.03.88123.05.89  I 
I  I  I  I  I  I  I  I  I  I  I  I 
I Fuc i d i c  acid  I  ~ I  CR  I  ~ I  *  I  1tJr  I  PUT  I  *  I  AA  I  *  I  *  *  *  I 
167,  15.6.88  126.09.881  112.12.001  122.06.88101.06.881  108.02.891  I  I 
I  I  I  I  I  I  I  I  I  I  I  I 
I  Ac ides  Bl'ti nes  I  CR  I  *  I  *  I  PUT  I  1tJr  I  *  I  *  I  *  I  *  I  *  *  *  I 
169,  15.6.88  I  I  I  117.06.88111.02.001  I  I  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I 
IEnoxaparine  I  1UT  I  1UT  I  1UT  I  1UT  I  CR  I  PUT  I  PUT  I  AA  I  AA  I  AA  I  *  1UT  I 
170,  15.6.88  123.08.88114.6.89  118.01.89117.06.881  119.10.88129.08.89131.07.00119.08.88101.03.891  23.10.001 
I  I  I  I  I  I  I  I  I  I  I  I  I  I 
!Rifampicin  isoniazid/pyr.l  1UT  I  *  I  1UT  I  PUT  I  *  I  *  I  *  I  AUT  I  AUT  I  *  I  *  I  CR  I 
171,  14.9.88  109.01.891  131.01.89130.09.881  I  I  108.02.89126.10.881  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  I  I 
IN i za tid  i ne  I  *  I  *  I  ~ I  *  I  *  I  /UT  I  *  I  *  I  *  I  *  I  *  I  CR  I 
172,  15.6.88  I  I  115.12.881  I  101.07.881  I  I  I  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  I  I 
IAtenolol  I  *  I  *  I  f.Uf  I ·  *  I  *  I  *  I  *  I  *  I  PUT  I  *  I  *  I  CR  I 
173,  14.9.88  I  I  117.08.891  I  I  I  1  126.10.881  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  I  I 
(1)  An  applicant rmy  subs~ently appeal  the Mnber State rut ing,  using national  procedlres. 
'  ..  ~~ Mlrch  1993 
cn.PLETID M..J.. T I-STATE  PR;X :R lR:S 
ltJT .. au tori  sat ion  REf(1)  - refusaiAvithdr~~l  CR- country of origin  * - not  concerned 
I 
I  PAYS  I  COUNTRIES 
I  I  I  I  I  I  I  I 
I  MDICJM:NT  I  I  BE  I  [)(  I  EE  I  ESP  FR  I  ffi  I  IRL  I  IT  I  LLOC  I  NL  I  FO  I  LJ( 
I  Cpinion No./Date  I  I  I  I  I  I  I  I  I  I  I 
I  I  I  I  I  I  I  I  .  I  I 
I  I  I 
ISalbutamol  Inhaler  I  PUr  I  PUT'  I  •  I  •  IUT  I  IUT  I  •  I  PUT'  I  IUT  I  IUT  I  *  I  CR 
142,  12.11.86  119.08.91130.06.861  I  17.04.87129.01.871  130.12.86119.12.86112.06.871  I 
I  I  I  I  I  I  I  I  I  I  I  I 
IKetoprofen  I  AA  I  PUT'  I  *  I  *  *  I  *  I  *  I  *  I  IUr  I  PUT'  I  *  I  CR 
143,  11.3.87  120.01.88105.02.871  I  I  I  I  127.11.86119.06.871  I 
I  I  I  I  I  I  .  I  I  I  I  I  I 
IBisoprolol  fUTarate  I  *  I  *  I  rn  I  fiJT'  *  I  ,AUT  I  ,AUT  I  fiJT'  I  IUr  I  PUT  I  *  I  PUT  I 
144,  11.3.87  I  I  I  116.00.87  112.01.88118.06.87101.03.89119.12.86106.10.871  118.12.871 
I  I  I  I  I  I  I  I  I  I  I  I 
IPrazosin  I  REF  I  *  I  IUr  I  J.UT  J.UT  I  REF  I  CR  I  REF  I  REF  I  REF  I  *  *  I 
145,  10.6.87  117.08.871  I  123.03.87  14.02.00100.05.881  115.05.87110.07.87128.07.871  I 
I  I  I  I  I  I  I  I  I  I  I  I 
IFibr.extr.  testa triticunl  *  I  .  *  I  REF  I  *  I  J.UT  I  IUT  I  *  I  *  I  •  I  *  *  CR  I 
146,  16.9.87  I  I  116.06.891  126.01.88126.01.881  I  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I 
ITixocortol  pivalate  I  *  I  PUT'  I  •  I  *  I  CR  I  •  I  INF  ·I  *  I  IUT  I  •  *  REF  I 
147,  14.10.87  I  128.10.871  I  I  I  103.11.921  100.01.881  17.12.001 
I  I  I  I  I  I  I  I  I  I  I  I 
I Iron gluconate  I  ,AUT  I  *  I  rn  I  *  I  *  I  *  I  *  I  JIUf  I  IUT  I  *  *  *  I 
148,  7.7.87  119.01.881  I  I  I  I  I  I  05.03.  00130.09.871  I 
I 
I  I  I  I  I  I  I  I  I  I  I  I 
I Inhaler salbutamol  I  AA  I  ,AUT  I  REF  I  fiJT'  I  .AUT  I  .AUT  I  CR  I  fiJT'  I  .AUT  I  PUT  *  .AUT  I 
149,  7.7.87  104.00.91125.04.88112.10.88121.10.87130.06.87111.03.881  I 02.03.  00 I 00.01 •  88128.00. 88  01.09.871 
I  I 
I  I  I  I  I  I  I  I  I  I  I  I  I 
ISelegi I ine 1-CI  I  PUT  I  *  I  rn  I  fiJT'  I  *  I  *  I  *  I  *  I  IUT  I  REF  I  *  I  *  I 
15(),  16.9.87  120.01.881  I  109.10.871  I  I  I  100.01.88114.09.881  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  I  I 
ITetratolol  I  IUT  I  ltJf  I  IUT  I  REF  I  rn  I  JIUf  I  PUT  I  JIUf  I  IUT  I  PUT  I  *  I  REF  I 
151,  17.2.88  123.08.88115.03.88123.03.89109.03.881  104.03.88121.04.88110.04.89130.09.87112.09.881  117.12.001 
I  I  I  I  I  I  I  I  I  I  I 
I  I  I  I  I 
( 1)  M  applicant rm.y  subseq.tent ly appeal  the Mnber State ruling,  using national  proced.l.res. Mlrch  1993 
ro.REJB) M.L T I ...sTAlE  ffl'XB) .Fe 
AJr - autor isat ion  REf( 1)  - refusal/wi thdraYal  CR  - country of origin  * - not  concerned 
I 
I  PAYS  I  COUNTRIES 
I  I  I  I  I  I  I  I  I  I  I  I  I 
I  MD llA'v£NT I  I  EE  I  [l(  I  a:  I  ESP  I  FR  I  ffi  I  IRL  I  IT  I  LU<  I  NL  I  FO  I  U< 
I  Qlinion No./Date  I  I  I  I  I  I  I  I  I  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  I 
ltmtocloprcmide~l  I  REF  I  PUT  I  REF  I  REF  I  *  I  REF  I  <R  I  REF  I  REF  I  PUT  I  *  I  * 
152.  16.9.87  121.11.87130.09.87104.11.87109.10.871  ' 109.11.871  124.10.87106.01.88119.05.881  I 
I  I  I  I  I  I  I  I  I  I  I  I  I 
IFiura.zeni I  I  AA  I  PUT  I  PUT  I  PUT  I  <R  I  AA  I  ,6UT  I  AA  I  AA  I  PUT  I  *  I  PUT 
153;  14.10.87  118.01~88128.10.87131.10.88121.10.871  131.03.88118.02.88101.02.89130.09.87127.04.881  129.03.88 
I  I  I  I  I  I  I  I  I 
IFenticonazole  1- *  I  *  I  AA  I  *  *  I  *  ,6UT  CR  I  *  I  *  *  I  * 
154.  16.12.87  I  I  131.01.91 f  I  18.02.88  I  I  I 
I  I  I  I  I  I  I  I  I 
IPropanolol  ~~  I  *  I  flUf  I  *  I  •  <R  I  PUT  PUT  .  REF  I  *  I  PUT  *  I  PUT 
155.  14.10.87  I  128.10.871  I  122.01.88 18.02.88 14.05.901  114.12.88  105.02.91 
I  I  I  I  I  I  I  I  I 
I Leuprore  I i ne  I  AA  I  *  I  *  I  •  ffi  I  *  *  AA  I  *  I  *  *  I  *  156,  14.9.88  109.08891  I  I  I  13.02.891  I  I 
I  I  I  I  I  I  I  I  I 
IDihydrocodeine tatrate  I  AA  I  REF  I  IUr  I  PUT  PUT'  I  PUT  *  REF  I  PUT'  I  REF  *  I  CR 
157.  17.2.88  124.05.88126.09.89128.12.88104.03.88 31.01.89109.08.88  W.03.88130.03.88106.02.89  I 
I  I  I  I  I  I  I  I  I  I  I 
ICiprofloxacine  I  *  I  *  I  *  I  IUr  I  *  I  PUT  *  I  *  I  *  I  *  *  I  CR 
158,  16.12.87  I  I  I  104.02.881  106.04.88  I  I  I  I 
I  I  I  I  I  I  I  I  I  I  I 
ltlesalazine  I  PUT'  I  fiJT  I  CR  I  * .  I  *  I  PUT  •  I  *  I  *  I  PUT  *  I  PUT 
ISO,  16.12.88  116.05.88111.01.881  I  I  105.02.88  I  I  118.03.88  121.03.89 
I  I  I  I  I  I  I  I  I  I  I  I  I  I 
IFrusanide ani lor  ide 1-CI  I  PUT  I  fiJT  I  *  I  *  I  *  I  ftUr  I  *  I  ,6UT  I  PUT  I  *  I  *  I  CR  I 
161,  17.2.88  101.07.88129.03.891  I  I  117.a>.881  102.02.89130.03.881  I  I  I 
I  I  I  I  I  I  I  I 
I  I  I  I  I  I  I 
IZuclopethixol  I  *  I  CR  I  *  I  *  I  *  I  ltJf 
I 
*  I  PUT'  I  *  I  *  I  *  I  *  I  I 
162,  13.4.88  I  I  I  I  I  125.02.881  120.05.881  I  I  I 
I  I  I  I  I  I  I  I  I  I  I  I  I 
(1) An  applicant rmy subseq.tently appeal  the Mnber State ruling,  using national  proced.lres. 